[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 155
1. Gilbert JA, Frederick LM, Ames MM: The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res; 2000 Nov;6(11):4365-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells.
  • The carcinoid tumor is an uncommon neuroendocrine neoplasm the hallmark of which is excessive serotonin production.
  • In studying kinetics of tryptophan hydroxylase and aromatic-L-amino acid decarboxylase (AAAD) in human carcinoid hepatic metastases and adjacent normal liver (J. A.
  • Pharmacol., 50: 845-850, 1995), we identified one significant difference: the Vmax of carcinoid AAAD was 50-fold higher than that in normal liver.
  • Here, we report Western and Northern analyses detecting large quantities of AAAD polypeptide and mRNA in human carcinoid primary as well as metastatic tumors compared with normal surrounding tissues.
  • To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.
  • On exposure to other human tumor lines, carbidopa was lethal only to NCI-H146 and NCI-H209 small cell lung carcinoma (SCLC) lines (IC50 = 12 +/- 1 microM and 22 +/- 5 microM, respectively).
  • Carbidopa (100 microM) decreased growth of (but did not kill) SK-N-SH neuroblastoma and A204 rhabdomyosarcoma cells and did not affect proliferation of DU 145 prostate, MCF7 breast, or NCI-H460 large cell lung carcinoma lines.
  • The rank order of lines by AAAD activity was NCI-H146 > NCI-H209 > SK-N-SH > NCI-H727, whereas A204, DU 145, MCF7, and NCI-H460 had no measurable activity.
  • For lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma), AAAD activity was correlated with the potency of carbidopa-induced cytotoxicity.
  • However, carcinoid cell death was not solely attributable to complete inhibition of either AAAD activity or the serotonin synthetic pathway.
  • In further evaluating potential applications of these findings with carbidopa, we determined that sublethal doses of carbidopa produced additive cytotoxic effects in carcinoid cells in combination with etoposide and cytotoxic synergy in SCLC cells when coincubated with topotecan.
  • [MeSH-major] Aromatic Amino Acid Decarboxylase Inhibitors. Carbidopa / pharmacology. Carcinoid Tumor / drug therapy. Carcinoma, Small Cell / drug therapy. Enzyme Inhibitors / pharmacology. Lung Neoplasms / drug therapy
  • [MeSH-minor] Cell Division / drug effects. Humans. Ileum / enzymology. Liver / enzymology. Microscopy, Electron. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11106255.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 58450
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Aromatic Amino Acid Decarboxylase Inhibitors; 0 / Enzyme Inhibitors; MNX7R8C5VO / Carbidopa
  •  go-up   go-down


2. Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A: ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol; 2010 Apr;5(4):453-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
  • The associations of ERCC1 and Ki67, clinical features and survival in small cell lung carcinoma (SCLC), typical carcinoid (TC), atypical carcinoid (AC), and large cell neuroendocrine carcinoma (LCNEC) were determined.
  • MATERIALS AND METHODS: We included a consecutive series of 186 patients with SCLC treated with platinum-based chemotherapy and surgically treated patients with TC (n = 48), AC (n = 15) and LCNEC (n = 27).
  • RESULTS: The expression of ERCC1 was different among the different tumor types (p < 0.001).
  • For patient with limited disease as well as extensive disease SCLC, no association of ERCC1 expression with survival was observed (p = 0.59).
  • However, only 10% of SCLC tumors expressed ERCC1.
  • A difference of the percentage of Ki67 LI was observed for the different tumor types (p < 0.001).
  • The difference between TC and AC was significant (p = 0.02), as was the difference between low grade (TC+AC) and high grade NE (LCNEC + SCLC) (p < 0.001).
  • CONCLUSION: ERCC1 expression in SCLC treated with platinum-based chemotherapy has no impact on survival.
  • High expression of ERCC1 in TC might represent a clue to the failure of platinum-based therapy in these patients.
  • ERCC1 expression has prognostic impact in lung carcinoids.
  • Ki 67 might be considered as a supplementary test to the histopatologic classification of NE tumors.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Ki-67 Antigen / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoid Tumor / metabolism. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Neuroendocrine Tumors / metabolism. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Organoplatinum Compounds / therapeutic use. Prognosis. Retrospective Studies. Small Cell Lung Carcinoma / metabolism. Small Cell Lung Carcinoma / mortality. Small Cell Lung Carcinoma / pathology. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2010 Nov;5(11):1876-7 [20975385.001]
  • (PMID = 20104194.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Organoplatinum Compounds; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  •  go-up   go-down


3. Pelosi G, Volante M, Papotti M, Sonzogni A, Masullo M, Viale G: Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. Q J Nucl Med Mol Imaging; 2006 Dec;50(4):272-87
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy.
  • Neuroendocrine tumors of the lung are carcinomas characterized by different impact on the patients' prognosis, ranging from relatively indolent, low- to intermediate-grade neoplasms with longer life expectation (i.e., typical and atypical carcinoids) to very aggressive and poorly differentiated neoplasms with dismal prognosis (i.e., large cell neuroendocrine carcinoma and small cell lung cancer).
  • The standard treatment of typical or atypical carcinoids is the complete surgical resection, whereas the role of radio-chemotherapy in a multimodality treatment or for palliation remains controversial.
  • Conversely, high-grade neuroendocrine carcinomas are in primis treated by aggressive combination chemotherapy, deserving surgical resection for uncommon low-stage tumors.
  • Since evidence has been accumulated that neuroendocrine tumors of the lung are supplied with a wide array of peptide receptors detectable on cell membranes by immunohistochemical methods, innovative strategies for diagnosis and radiometabolic therapy have been devised to target these molecules for the correct clinical management of the patients.
  • In this paper, the structural and functional aspects and the clinical applications of the detection of several peptide receptors in pulmonary neuroendocrine tumors will be reviewed, including somatostatin receptors, vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide family receptors, cholecystokinin /gastrin receptors, bombesin/gastrin releasing peptide receptors, neurotensin receptors, substance P receptors, neuroepeptide Y receptors, calcitonin/calcitonin gene-related peptide receptors, atrial natriuretic peptide receptors, glucagon-like-peptide-1 receptors, oxytocin receptors and endothelin receptors.
  • Only a detailed knowledge of the peptide receptor distribution in these tumor types, especially in uncommon neoplasms such as atypical carcinoids and large cell neuroendocrine carcinomas, is pivotal for planning the most adequate interventions for the patients' diagnosis and therapy.
  • [MeSH-major] Carcinoma, Neuroendocrine. Lung Neoplasms. Radioisotopes. Receptors, Peptide / metabolism
  • [MeSH-minor] Drug Delivery Systems / methods. Humans. Radiopharmaceuticals / pharmacokinetics. Radiopharmaceuticals / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043625.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Receptors, Peptide
  • [Number-of-references] 166
  •  go-up   go-down


Advertisement
4. Koletsis EN, Prokakis C, Karanikolas M, Apostolakis E, Dougenis D: Current role of surgery in small cell lung carcinoma. J Cardiothorac Surg; 2009;4:30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current role of surgery in small cell lung carcinoma.
  • Small cell lung carcinoma represents 15-20% of lung cancer.
  • Is is characterized by rapid growth and early disseminated disease with poor outcome.
  • For many years surgery was considered a contraindication in Small Cell Lung Cancer (SCLC) since radiotherapy and chemoradiotherapy were found to be more efficient in the management of these patients.
  • Never the less some surgeons continue to be in favor of surgery as part of a combined modality treatment in patients with SCLC.
  • The reevaluation of the role of surgery in this group of patients is based on clinical data indicating a much better prognosis in selected patients with limited disease (T1-2, N0, M0), the high rate of local recurrence after chemoradiotherapy with surgery considered eventually more efficient in the local control of the disease and the fact that surgery is the most accurate tool to access the response to chemotherapy, identify carcinoids misdiagnosed as SCLC and treat the Non Small Cell Lung Cancer component of mixed tumors.
  • Performing surgery for local disease SCLC requires a complete preoperative assessment to exclude the presence of nodal involvement.
  • In stage I surgery must always be followed by adjuvant chemotherapy, while in stage II and III surgery must be planned only in the context of clinical trials and after a pathologic response to induction chemoradiotherapy has been confirmed.
  • [MeSH-major] Lung Neoplasms / surgery. Small Cell Lung Carcinoma / surgery
  • [MeSH-minor] Combined Modality Therapy. Evidence-Based Medicine. Humans. Neoplasm Staging. Patient Selection. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1988 May;6(5):832-8 [2835443.001]
  • [Cites] J Thorac Cardiovasc Surg. 1983 Oct;86(4):498-506 [6312199.001]
  • [Cites] Ann Thorac Surg. 1992 Sep;54(3):498-501 [1324656.001]
  • [Cites] Chest. 1994 Dec;106(6 Suppl):320S-323S [7988254.001]
  • [Cites] Chest. 1997 Apr;111(4):1089-93 [9106591.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Nov;12(5):689-93 [9458136.001]
  • [Cites] Eur J Cardiothorac Surg. 1998 Oct;14(4):398-402 [9845145.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):265-71 [9920950.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jan;129(1):64-72 [15632826.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 May;129(5):977-83 [15867769.001]
  • [Cites] Ann Thorac Surg. 2005 Aug;80(2):418-21; discussion 422 [16039176.001]
  • [Cites] Lancet. 2005 Oct 15-21;366(9494):1385-96 [16226617.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):70-6 [16382115.001]
  • [Cites] Lung Cancer. 2006 Jun;52(3):263-4 [16677735.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Aug;30(2):212-6 [16829087.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2006 Fall;18(3):211-6 [17185181.001]
  • [Cites] Ann Thorac Surg. 2007 Sep;84(3):967-71 [17720409.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):324S-339S [17873178.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183(12):679-84 [18040612.001]
  • [Cites] J BUON. 2007 Oct-Dec;12(4):453-61 [18067202.001]
  • [Cites] J Thorac Oncol. 2008 Nov;3(11):1267-71 [18978561.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4665-72 [12488411.001]
  • [Cites] Cancer Control. 2003 Jul-Aug;10(4):289-96 [12915807.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):176-81 [14508850.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Oct;15(4):448-56 [14710387.001]
  • [Cites] Thorac Surg Clin. 2004 May;14(2):271-81 [15382303.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Oct;26(4):782-6 [15450573.001]
  • [Cites] Am J Med. 1969 Apr;46(4):516-25 [5791000.001]
  • [Cites] Lancet. 1973 Jul 14;2(7820):63-5 [4123619.001]
  • [Cites] J Thorac Cardiovasc Surg. 1982 Oct;84(4):481-8 [6289013.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Mar;101(3):385-93 [1847981.001]
  • (PMID = 19589150.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC2716318
  •  go-up   go-down


5. Ruggieri M, Scocchera F, Genderini M, Mascaro A, Paolini A: Therapeutic approach of carcinoid tumours of the lung. Eur Rev Med Pharmacol Sci; 2000 Jan-Apr;4(1-2):43-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic approach of carcinoid tumours of the lung.
  • In the carcinoid tumours of the bronchopulmonary tract surgical resection is still the primary goal.
  • Many problems are, however, unclear: the extent of resection, formal lymph node dissection or not, the role of Video-Assisted Thoracic Surgery (VATS) and of the multidisciplinary approach.
  • In the Department of Surgical Sciences and Applied Medical Technologies, "La Sapienza", Rome's University, from 1969 to 1994, we observed 18 patients with carcinoid tumours of the lung: 13 typical carcinoid (TC) and 5 atypical carcinoid (AC).
  • In our series, the choice of therapeutic procedure was made on the basis of histological criteria and TNM classification.
  • We performed 3 conservative and 10 extensive resections on typical carcinoid and 5 extensive resections on atypical carcinoid tumours.
  • In our series VATS played a minor therapeutic role.
  • Formal lymph node dissection was carried out on all our patients except in the cases of those with typical carcinoid tumours without enlarged hilar and mediastinal lymph nodes.
  • The efficacy of adjuvant chemotherapy in carcinoid tumours treatment is controversial and will be confirmed by further trials.
  • In bronchial carcinoid tumours the long-term prognosis is excellent.
  • In our series the ten-year survival rate is 77 per cent in typical carcinoid and 40 per cent in atypical carcinoid cases.
  • [MeSH-major] Carcinoid Tumor / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11409188.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Wu R, Fang W, Lin L: [The clinical analysis of lung cancer with paraneoplastic syndrome as initial symptom]. Zhongguo Fei Ai Za Zhi; 2003 Jun 20;6(3):204-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical analysis of lung cancer with paraneoplastic syndrome as initial symptom].
  • BACKGROUND: To investigate the clinical characteristics and diagnosis of lung cancer with paraneoplastic syndrome as initial symptom.
  • METHODS: The clinical data of 168 cases of lung cancer with paraneoplastic syndrome as initial symptom were analysed from Jan.
  • (1) Among the patients with lung cancer in the hospital, 11.8% (168/1 426) had paraneoplastic syndrome as initial symptom.
  • There were 138 cases aged above 45 (82.1%) and 116 with smoking history (69.0%). (2)There were 62 cases of small cell lung cancer (36.9%) and 102 non small cell lung cancer (60.7%) and 4 carcinoid (2.4%).
  • Thirty-three cases (37.5%) were central type and 82 (48.8%) peripheral type and 23 (13.7%) diffuse type. (3) The patients with paraneoplastic syndrome included: 48 cases of osteoarthopathy (28.6%), 27 cachexia (16.1%), 23 cancerous fever (13.7%), 14 myasthenia (8.3%), 12 vegetative nerve hyperfunction (7.1%), 11 cerebellar cortex degeneration (6.5%), 9 acanthosis nigricans (5.4%), 8 cutaneous pigmentation (4.8%), 7 dermatomyositis (4.2%), 5 encephalopathy (3.0%), and 4 gynecomastia (2.4%). (4)The misdiagnosis rate of the first consultation was 44.6% (75/168). (5)Initial chest X-ray positive rate was 61.9% (104/168); initial CT positive rate was 78.6% (132/168). (6)One hundred and thirty-two cases accepted the treatment of lung cancer: 32 cases accepted pure operation, 8 cases accepted pure chemotherapy, 35 cases accepted operation and chemotherapy, 39 cases accepted chemotherapy and radiotherapy, 18 cases accepted operation and chemotherapy and radiotherapy.
  • Totally 8 cases were dead and 17 cases had abandoned treatment.
  • One hundred and seven cases had improvement after complex treatment of lung cancer, including 83 cases with improvement or disappearance of paraneoplastic syndrome, 18 cases with no change, and 6 cases exacerbated.
  • CONCLUSIONS: The lung cancer with paraneoplastic syndrome as initial symptom is difficult to diagnose because of its latent onset.
  • The knowledge of paraneoplastic syndrome should be improved, chst X-ray or CT examination should be done for the high risk group of lung cancer with paraneoplastic syndrome, and these strategies could decrease misdiagnosis rate and increase diagnosis rate of lung cancer in early stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21266121.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Rossi G, Cavazza A, Marchioni A, Migaldi M, Bavieri M, Facciolongo N, Petruzzelli S, Longo L, Tamberi S, Crinò L: Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol; 2003 Oct;16(10):1041-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kit expression in small cell carcinomas of the lung: effects of chemotherapy.
  • A significant number of small cell lung carcinomas shows overexpression of the proto-oncogene c-kit product, a tyrosine kinase known as Kit or CD117.
  • This molecular pathway seems somewhat implicated in promoting the neoplastic growth of small cell lung carcinoma.
  • The current pharmacological availability of its selective inhibitor, together with the promising clinical results in the management of CD117-positive neoplasms such as advanced gastrointestinal stromal tumors, aroused great interest among oncologists in also adopting this therapeutic strategy in other CD117-positive tumors.
  • We evaluated a series of 27 small cell lung carcinomas, comparing the expression of CD117 of the primary naïve tumor (before first-line chemotherapy) with the expression of the same neoplasm after postchemotherapy relapse.
  • At diagnosis, 21 of 27 cases (78%) showed strong immunoreactivity for CD117.
  • Among these 21 originally positive tumors, CD117 remained overexpressed in 10 after relapse (48%), whereas the other 11 cases became negative.
  • No originally CD117-negative small cell carcinomas displayed immunoreactivity after chemotherapy.
  • CD117 expression was not statistically correlated with overall survival, occurrence of chemoresistance, or clinical response to chemotherapy.
  • We also evaluated CD117 expression in a series of 46 surgically resected non-small cell lung carcinomas (8 squamous cell carcinomas, 10 adenocarcinomas, 5 pleomorphic carcinomas, 10 typical and 3 atypical carcinoids, and 10 large cell neuroendocrine carcinomas).
  • Apart from small cell carcinomas, CD117 overexpression was observed in 6 of 10 large cell neuroendocrine carcinomas, whereas all the other histotypes resulted unstained.
  • We speculate that loss of CD117 expression after chemotherapy in a high proportion of SCLC indicates that in this tumor, Kit unlikely represents the product of a constitutive mutation, as instead shown in gastrointestinal stromal tumors.
  • Keeping this finding in mind, oncologists could re-test CD117 expression in relapsing small cell lung carcinomas in order to establish the best candidates for enrollment in ongoing clinical trials with Kit inhibitors.
  • Practically speaking, CD117 may be helpful in discriminating between pulmonary high-grade neuroendocrine tumors and other histotypes, but pathologists should be aware that treated small cell lung carcinomas may remain unstained in a not insignificant number of cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / metabolism. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14559988.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Tesei A, Ricotti L, De Paola F, Amadori D, Frassineti GL, Zoli W: In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res; 2002 Jan;8(1):233-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Multitargeted antifolate (MTA) and gemcitabine (GEM) have shown preclinical and clinical activity in tumor histotypes such as colon, renal, small and non-small cell lung cancers, hepatomas and carcinoid tumors.
  • The type and degree of drug interactions were not paralleled by apoptosis, which was almost always negligible, or by the type and persistency of the cell cycle perturbations.
  • CONCLUSIONS: Our results indicate that the sequential administration of GEM --> MTA provides the greatest benefit in the clinical treatment of colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Folic Acid Antagonists / therapeutic use. Glutamates / therapeutic use. Guanine / therapeutic use
  • [MeSH-minor] Apoptosis / drug effects. DNA, Neoplasm / metabolism. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Interactions. Drug Resistance, Neoplasm. Drug Therapy, Combination. Flow Cytometry. Humans. In Situ Nick-End Labeling. Pemetrexed. Thymidylate Synthase / metabolism. Tumor Cells, Cultured / drug effects

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801564.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA, Neoplasm; 0 / Folic Acid Antagonists; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


9. Kong L, Wang Z, Wang R, Zhao X, Li B, Zhou T: [Clinical analysis of 17 cases of lung carcinoid tumor]. Zhonghua Jie He He Hu Xi Za Zhi; 2002 May;25(5):265-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 17 cases of lung carcinoid tumor].
  • OBJECTIVE: To study the classification and treatment modalities of lung carcinoid tumor.
  • METHODS: 17 cases of lung carcinoid tumor from May 1983 to May 1998 were reviewed and analysed.
  • RESULTS: Lung carcinoid tumors were classified into two sub-groups: typical carcinoid tumor and non-typical carcinoid tumor.
  • The prognosis of typical carcinoid tumor was better than that of non-typical carcinoid tumor.
  • 3-year survival was 5/6 for typical carcinoid tumor, 4/11 for non-typical carcinoid tumor.
  • There was no statistic significance in the treatment outcome between patients receiving operation + chemotherapy + radiotherapy and patients receiving chemotherapy + radiotherapy in non-typical carcinoid tumor.
  • CONCLUSION: Operation should be considered as the first choice for typical carcinoid tumor that has a good prognosis.
  • Non-typical carcinoid tumor tends to be metastatic and has a poor prognosis.
  • Chemotherapy should be considered as the first choice and radiotherapy as palliative for non-typical carcinoid tumor.
  • [MeSH-major] Carcinoid Tumor / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Lung / drug effects. Lung / radiation effects. Lung / surgery. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12133316.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Dahabreh J, Stathopoulos GP, Koutantos J, Rigatos S: Lung carcinoid tumor biology: treatment and survival. Oncol Rep; 2009 Mar;21(3):757-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung carcinoid tumor biology: treatment and survival.
  • A carcinoid tumor is a rare malignant disease which can be cured when localized and treated by surgery.
  • Chemotherapy is not effective, and somatostatin is used for palliation.
  • Rarely is the disease aggressive, and thus does not contribute to a shortening of patient survival.
  • The aim of this study was to define the treatment and survival of patients with primary lung carcinoid tumors.
  • All patients had histologically confirmed carcinoid tumors.
  • The site of the disease at diagnosis was the lung in all 43 patients.
  • One patient had the primary tumor excised for palliation as there were metastases in the liver.
  • Somatostatin palliative treatment was administered to 4 patients; 1 with liver and 3 with lung recurrence.
  • The median survival was not reached as all patients, apart from 2, were alive after a median follow-up of 5 years (mean survival 159 months).
  • As a rule, a carcinoid tumor is an extremely slow-growing disease with some rare exceptions.
  • All of our patients had primary lung disease.
  • All, apart from 2, were alive at the end of the study, and 93% were without recurrence for a duration of 6 months to 13 years.
  • The patients with liver metastases who underwent no specific treatment had a median survival as long as 8 years.
  • [MeSH-major] Carcinoid Tumor / mortality. Carcinoid Tumor / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Female. Hormones / therapeutic use. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Palliative Care / methods. Pneumonectomy. Somatostatin / therapeutic use

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212636.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hormones; 51110-01-1 / Somatostatin
  •  go-up   go-down


11. Kosmidis PA: Treatment of carcinoid of the lung. Curr Opin Oncol; 2004 Mar;16(2):146-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of carcinoid of the lung.
  • PURPOSE OF REVIEW: Pulmonary carcinoids are rare neuroendocrine malignancies that comprise 2% of primary lung tumors.
  • During the last few years, important information has appeared in the literature in relation to the histopathology, molecular biology, biologic behavior, and treatment of these tumors.
  • RECENT FINDINGS: Histologic subclassification of carcinoid tumors into atypical and typical is of paramount importance.
  • Genetic changes in these subclasses are now well-known and are helpful for the differentiation.
  • The biologic behavior of typical and atypical carcinoids is completely different, and treatment planning is based on this information.
  • Surgery is the treatment of choice for localized carcinoid tumors and includes lymphadenectomy.
  • In metastatic disease, chemotherapy with a cisplatin-based or streptozotocin-based combination is moderately effective.
  • SUMMARY: Pulmonary carcinoids are rare tumors, and our understanding of their histopathology and biologic behavior are the most important factors for treatment planning.
  • Surgery is the treatment of choice for cure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoid Tumor / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Humans. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15075907.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 34
  •  go-up   go-down


12. Hage R, de la Rivière AB, Seldenrijk CA, van den Bosch JM: Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol; 2003 Jul;10(6):697-704
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update in pulmonary carcinoid tumors: a review article.
  • Pulmonary carcinoid tumors are neuroendocrine malignant tumors that make up 1% to 2% of all lung tumors.
  • According to histopathologic criteria, carcinoids can be divided into typical (TC) and atypical (AC) carcinoids.
  • Carcinoids can be placed in a spectrum of neuroendocrine tumors, ranging from low-grade malignant TC to intermediate AC to high-grade large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
  • Familial pulmonary carcinoids are rare.
  • The most common symptoms are hemoptysis, cough, recurrent pulmonary infection, fever, chest discomfort and chest pain, unilateral wheezing, and shortness of breath.
  • Paraneoplastic syndromes are rare and include carcinoid syndrome, Cushing's syndrome, and ectopic growth hormone-releasing hormone secretion.
  • The diagnosis is usually established by flexible bronchoscopy and biopsy, although occasionally this can result in severe hemorrhage.
  • Immunoscintigraphy by somatostatin analogs can also be useful in diagnosis.
  • The treatment of choice is surgical resection, and prognosis is relatively good in TC, although it is worse in AC.
  • The role of radiotherapy and chemotherapy as part of multimodality treatment or palliation is still debated.
  • [MeSH-major] Carcinoid Tumor / pathology. Lung Neoplasms
  • [MeSH-minor] Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Combined Modality Therapy. Cough / etiology. Fever / etiology. Hemoptysis / etiology. Humans. Neoplasm Staging. Palliative Care. Prognosis. Radioimmunodetection. Radiotherapy, Adjuvant. Respiratory Sounds / etiology. Somatostatin

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839856.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  • [Number-of-references] 65
  •  go-up   go-down


13. Satoh M, Wakabayashi O, Araya Y, Jinushi E, Yoshida F: [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):798-804
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor].
  • A 58-year-old man with von Recklinghausen's disease was admitted for further investigation of right chest pain.
  • Chest X-ray revealed multiple emphysematous bullae in both lungs and a tumor shadow in the right upper lobe.
  • Bronchofiberscopy was performed, but an adequate specimen was not obtained.
  • The tumor was diagnosed as a non-small-cell lung cancer with direct invasion to the adjacent rib.
  • Although chemotherapy and radiotherapy resulted in decrease in tumor size, the tumor subsequently increased in size and the patient died 14 months after the first admission.
  • Autopsy revealed multiple emphysematous bullae, poorly differentiated adenosquamous cell carcinoma of the lung, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor.
  • This case suggests the possibility that von Recklinghausen's disease associated with emphysematous bullae is a risk factor for lung cancer.
  • It has also been suggested that the genetic abnormality responsible for von Recklinghausen's disease increases the risk for various types of malignancy.
  • Although von Recklinghausen's disease is reportedly associated with various malignant tumors, it is quite rare for von Recklinghausen's disease to be associated with triple non-neurogenic tumors.
  • Careful observation is mandatory for patients with von Recklinghausen's disease.
  • [MeSH-major] Autopsy. Carcinoid Tumor / etiology. Carcinoma, Adenosquamous / etiology. Duodenal Neoplasms / etiology. Gastrointestinal Stromal Tumors / etiology. Lung Neoplasms / etiology. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Pulmonary Emphysema / complications. Pulmonary Emphysema / diagnosis. Pulmonary Emphysema / pathology. Risk Factors

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827584.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


14. Borri A, Leo F, Galetta D, Veronesi G, Solli P, Petrella F, Gasparri R, Scanagatta P, Spaggiari L: [Technique, results and impact of induction chemotherapy in sleeve lobectomy for lung cancer]. Minerva Chir; 2006 Aug;61(4):307-13
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Technique, results and impact of induction chemotherapy in sleeve lobectomy for lung cancer].
  • [Transliterated title] Tecnica, risultati e ruolo della chemioterapia di induzione nella lobectomia con resezione/anastomosi bronchiale (sleeve).
  • AIM: The aim of this study was to evaluate the safety of continuous nonabsorbable (3/0 polypropylene) sutures for sleeve lobectomy, and the influence of induction chemotherapy on postoperative outcome in patients with lung malignancies.
  • METHODS: A review of a prospective database of a single surgeon identified 41 consecutive patients who underwent sleeve lobectomy from May 1998 to July 2003.
  • RESULTS: Twenty-four patients (59%) underwent induction chemotherapy.
  • Eight patients underwent reconstruction of the pulmonary artery.
  • There were 34 non-small cell lung cancers, 3 limited small cell lung cancers, 1 neuroendocrine large cell carcinoma, and 3 bronchial carcinoid tumors.
  • N2, N1, and N0 diseases were found in 13, 12 and 16 patients, respectively.
  • Post-operative morbidity and mortality were 14.5% (n=6) and 4.8% (n=2) (1 patient, 4%, after induction chemotherapy).
  • Late bronchial stenosis developed in 3 cases, but all were successfully medically treated.
  • Twenty-nine patients are still alive, 27 without evidence of disease.
  • Induction chemotherapy did not influence postoperative morbidity/mortality (chi2 test: P=0.64/P=0.56).
  • CONCLUSIONS: Continuous nonabsorbable suture for sleeve lobectomy is quick and technical easy to perform, with low postoperative morbidity/mortality; induction chemotherapy does not influence postoperative outcome in these patients.
  • [MeSH-major] Bronchi / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods. Suture Techniques
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Polypropylenes. Prospective Studies. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122763.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Polypropylenes
  •  go-up   go-down


15. Buonerba C, Gallo C, Di Lorenzo G, Romeo V, Marinelli A: Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung. Anticancer Drugs; 2010 Apr;21(4):465-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung.
  • Both typical carcinoid and atypical carcinoid (AC) of the lung are surgically curable, but AC carries a considerably worse prognosis because of a relatively high rate of recurrence.
  • Adjuvant therapy can be conducted with radiotherapy, chemotherapy, and somatostatin analogs (SST-As), but its effectiveness in preventing locoregional and distant recurrences is yet to be fully investigated.
  • A 48-year-old woman, presenting with AC, was free of both radiographical and biochemical signs of residual disease, after surgery and chemotherapy.
  • To prevent disease recurrence, she underwent long-term adjuvant treatment based on SST-As.
  • During the 10-year follow-up period, no side effects referable to SST-As have been reported and no evidence of recurrence of the disease has been detected.
  • In consideration of the relatively high recurrence rate of the disease and of excellent tolerance for SST-As, long-term adjuvant treatment based on SST-As could become a therapeutic option for surgically cured patients with AC.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / drug therapy. Lung Neoplasms / drug therapy. Somatostatin / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075713.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 51110-01-1 / Somatostatin
  •  go-up   go-down


16. Bajetta E, Procopio G, Catena L, Ferrari L, Ricci S, Iacobelli S, Cartenì G, De Braud F, Loli P, Vezzadini P: A multicentric randomized phase III study to evaluate the equivalence between lanreotide PR 60 mg vs lanreotide Autogel 120 mg in well-differentiated neuroendocrine tumours (NETs). J Clin Oncol; 2004 Jul 15;22(14_suppl):4154

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicentric randomized phase III study to evaluate the equivalence between lanreotide PR 60 mg vs lanreotide Autogel 120 mg in well-differentiated neuroendocrine tumours (NETs).
  • : 4154 Background: Somatostatin analogues represent the treatment of choice for inoperable well-differentiated NETs, mainly for symptomatic patients (pts).
  • METHODS: Sixty pts with histologically proven well-differentiated NETs (accordingly to the WHO classification) were randomized to receive lanreotide prolonged release (PR) 60 mg every 3 weeks or the new drug formulation Autogel (ATG) 120 mg every 6 weeks, Primary end point was to show the equivalence between the PR and the ATG formulations in terms of clinical, symptomatic and biochemical responses.
  • Primary tumour site: small bowel 37%, pancreas 27%, lung 13%, unknown 18% and others 5%.
  • Most of the pts were pretreated: 54% with octreotide and 22% with chemotherapy.
  • Thirty-one percent of pts had carcinoid syndrome and 85% of pts had increased levels of chromogranin A.
  • Six pts are still on treatment.
  • Partial tumour responses were observed in 7% (95% C.I.: 2-16%) and 0 pts treated with PR and ATG formulation, respectively.
  • Disease stabilization was demonstrated in 75% (C.I.: 59-90%) and 77% (C.I.: 62-92%) of the pts (PR vs ATG) and disease progression in 20% (C.I.: 6-34%) and 23% (C.I.: 8-38%) of the pts (PR vs ATG).
  • There were no side effects leading to a treatment discontinuation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013779.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Dudek A, Larson T, Mellskog CE, Bloss LP, Obasaju C: A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors.
  • The optimal sequence and schedule of both drugs is currently unknown.
  • Dose Escalation Levels with DLTs [Figure: see text] Results: Thus far, 24 patients (13 female, 11 male) with 1 or no prior chemotherapy; median age 61 (range 39 - 80); ECOG PS 0 (11), 1 (13); diagnoses: lung (10), malignant pleural mesothelioma (3), pancreas (3), breast (2), atypical carcinoid tumor (2), head and neck (1), ovarian (1), skin (1), unknown primary (1) have received a current total of 87 cycles (range 1-13/ patient).
  • MTD was established at dose level 5 (G 1500 mg/m2 and P 600 mg/m2) with two patients out of 6 experiencing neutropenic fever (NF).
  • Plans are to study this schedule in phase 2 trials in many tumor types where G and P are known to be active.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016894.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Horn L, Milne G, Sandler A, Morrow J, Carbone D, Shyr Y, Hayes A, Campbell N, Johnson DH: Urine PGE-M to assess prostaglandin E2 (PGE&lt;sub&gt;2&lt;/sub&gt;) levels in non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urine PGE-M to assess prostaglandin E2 (PGE<sub>2</sub>) levels in non-small cell lung cancer (NSCLC).
  • METHODS: Eligibility: previously treated NSCLC, PS 0-2, evaluable/measurable disease, adequate marrow, renal & hepatic function, no current NSAID or sulfa allergy.
  • Pts with ≥70% decline in PGE-M continued on C + D 75 mg/m<sup>2</sup> or pemetrexed 500 mg/m<sup>2</sup> q3wk x 4 cycles followed by maintenance C 400 mg PO bid until PD or drug intolerance.
  • RESULTS: 21 pts enrolled; F=7, M=14; 2 ineligible (1 carcinoid; 1 elevated LFT); 2 stopped C early (1 ARF; 1 pruritus).
  • Males had higher pre- treatment PGE-M (44 vs. 28.8 ng/mg Cr; P=0.21).
  • Males had a significant decrease in mean PGE-M levels after C (78%; P=0.011); a similar albeit not significant change occurred in females (P=0.12).
  • 12 screened pts (57%) had a ≥70% decline in PGE-M & received treatment with C + chemotherapy; 8 pts are evaluable for response; SD = 6; PD = 2.
  • Treatment was well tolerated with no cardiac toxicities noted.
  • [Funding: VICC Lung Cancer SPORE CA90949].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962575.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Chiappori A, Simon GR, Kvols L, Tetteh L, Mahany JJ, Lush R, Sullivan DM: Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2132

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors.
  • Carboplatin(C), Irinotecan(T) and Etoposide (E) are drugs with a broad spectrum of activity.
  • METHODS: Four previously treated patients with advanced malignancies were enrolled in the first dose level of C at AUC of 2.5 on days 1 & 8; T at 60mg/m<sup>2</sup> on days 1 & 8 and E at 60 mg/m<sup>2</sup> on days 2 & 3.
  • RESULTS: A total of 10 patients were enrolled from April 2002 to October 2002.Patient characteristics were M/F 5/5; age range 24 to 65, ECOG PS 0/1=1/9; number of prior treatments 0/1/2/3= 4/2/3/1; median number of cycles given=3 (range 1 - 8).
  • Tumor types enrolled were NSCLC = 3, Carcinoid = 3, and 1 each of Head and Neck Cancer, Mesothelioma, Sarcoma and Islet Cell Cancer of the pancreas.
  • One patient died from massive pulmonary hemorrhage secondary to progressive disease in the presence of normal platelet count.
  • The subsequent cohort of 6 patients tolerated chemotherapy well with no first-cycle or second-cycle grade III or IV neutropenia or thrombocytopenia.
  • Five of the 8 evluable patients had SD, 2 of whom had MR.
  • Further dose escalation was not attempted owing to 2/2 patients experiencing Grade IV neutropenia in the first cohort.
  • CONCLUSIONS: The recommended phase II dose for this regimen is C at AUC of 2.5 on days 1 & 8, T at 60mg/m<sup>2</sup> on days 1 & 8 and E at 50mg/m<sup>2</sup> on days 2 & 3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Gupta V, Weigand T, Rangineni R: Phase I-II dose escalation study of celecoxib (C) in combination with paclitaxel (T) and carboplatinum (CP) in non small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7310

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I-II dose escalation study of celecoxib (C) in combination with paclitaxel (T) and carboplatinum (CP) in non small cell lung cancer (NSCLC).
  • : 7310 Background: Preclinical data suggests COX-2 inhibitors prevent development of cancer,shrink established tumors,and inhibit angiogenesis in dose dependent manner with "optimal"blood levels of 1.8-5ug/ml of celecoxib(C).
  • METHODS: 34 patients with inoperable stage I-III and IV, with evaluable disease and PS 1,2 received C and prophylaxis with H2 blockers or proton pump inhibitors for 7d prior to CP AUC- 6 q4wks and T60mg/m2 weekly for at least 4 mo.Dose escalation of C was after 4 patients at each dose level.
  • Tumor response was q8wks.
  • 2 patients had received prior non-taxane therapy.
  • There were18 patients with 800mg/d C, 10 with 1200mg/d C and 6 with 1600mg/d C.
  • Patients with StageI-III disease after 4mo induction chemotherapy received consolidation radiotherapy with or without chemotherapy.
  • RESULTS: The mean, range and n of blood levels( ng/ml ) of C were 1278,(600-2500),9;1866(1100-4200),6; and 2983,(1200-6100),7 respectively at 800,1200and 1600mg/d of C.
  • There were 22 patients evaluable for response with 3CR,6PR,10SD, 3 progressive after 4mo of therapy.
  • One stage IV patient with brain mets at 800mg of C died postop with GI bleed from incidental carcinoid of small bowel and one at 1600mg of C(blood level 1200ng/ml) after anticoagulation for DVT(INR 2.4), and one at 800mg mg of C from grade 4 neutropenia and pneumonia.
  • The MTD of celecoxib has not been reached.
  • 3. "Optimal" blood levels of celecoxib may not be easily achieved at 800mg/d of celecoxib and may require therapeutic monitoring to properly asses impact in clinical trials.
  • 4. The therapeutic role of celecoxib in combination with chemotherapy or by itself requires ongoing investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015039.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results.
  • : e14527 Background: Preclinical studies demonstrate synergistic anti-tumor activity with the combination of E + C.
  • METHODS: Patients received E per oral for days 1-21 of a 28 day cycle.
  • RESULTS: 24 patients enrolled: 13 M, 11F; median age 62 (32-77); median number of prior cytotoxic chemotherapy regimens 1 (0-3; 75% with prior RT).
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.
  • Minor response seen in pulmonary carcinoid (n = 1); prolonged SD ≥ 6 cycles seen in pulmonary carcinoid (n=2), basal cell carcinoma (n=1), and esthesioneuroblastoma (n=1).
  • CONCLUSIONS: Pending safety analysis at the final planned dose level, the phase II recommended dose is E 10 mg/day (days 1 - 21) + C 20 mg/m<sup>2</sup> (days 1, 8, and 15) on a 28-day cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Brown AB, Rudin C, Rizvi N, Travis W, Takebe N, James LP, Subzwari S, Tyson L, Markus S, Krug LM: Phase I study of obatoclax mesylate (GX15-070MS), a bcl-2 antagonist, plus topotecan in relapsed small cell lung carcinoma and other solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of obatoclax mesylate (GX15-070MS), a bcl-2 antagonist, plus topotecan in relapsed small cell lung carcinoma and other solid tumors.
  • : 3504 Background: Bcl-2 is a rational target in SCLC since it is overexpressed in 60%-90% of tumors and may play a role in resistance of SCLC to chemotherapy.
  • Obatoclax has growth inhibitory effects in several solid tumor cell lines and xenografts, with at least additive effects in combination with topotecan.
  • The primary objective of this study was to evaluate the safety profile and maximum tolerated dose (MTD) of obatoclax plus topotecan in patients with relapsed SCLC and other solid tumors.
  • Eligible patients were adults with solid tumors appropriate for treatment with topotecan.
  • RESULTS: 14 patients have been treated including 8 SCLC, 3 extrapulmonary small cell, 1 carcinoid, 1 Merkel cell and 1 melanoma previously treated with 1 or 2 lines of chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961280.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. McMullan DM, Wood DE: Pulmonary carcinoid tumors. Semin Thorac Cardiovasc Surg; 2003 Jul;15(3):289-300
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary carcinoid tumors.
  • Carcinoid tumors of the lung are an uncommon group of neoplasms of neuroendocrine origin.
  • Pulmonary carcinoid tumors are typically benign and slow growing.
  • Because these tumors are generally resistant to chemotherapy, complete surgical resection is the primary form of therapy.
  • Long-term survival for patients with typical carcinoid is excellent but is decreased in those with the atypical subtype.
  • Complete tumor resection with preservation of uninvolved pulmonary parenchyma remains the fundamental goal in the surgical treatment of this unusual clinical entity.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy
  • [MeSH-minor] Biopsy, Fine-Needle. Bronchoscopy. Diagnostic Imaging. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12973707.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 97
  •  go-up   go-down


24. Wirth LJ, Carter MR, Jänne PA, Johnson BE: Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer; 2004 May;44(2):213-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.
  • STUDY OBJECTIVES: To determine the outcome of patients with pulmonary typical and atypical carcinoid tumors treated with chemotherapy with or without radiotherapy.
  • METHODS: Patients with pulmonary neuroendocrine tumors treated at our institution from 1990 to 2001 were identified.
  • The medical records of patients with diagnoses of typical or atypical pulmonary carcinoids were reviewed for the presence of evaluable disease, treatment with chemotherapy with or without radiotherapy, response to these treatments, survival and cause of death.
  • RESULTS: Eighteen patients with typical (n = 8) or atypical (n = 10) pulmonary carcinoid tumors who were treated with chemotherapy with or without radiotherapy were identified.
  • Of these, four received chemotherapy plus chest radiotherapy.
  • Three of these had stable disease and one had a partial response.
  • One of the patients with stable disease to chemoradiotherapy subsequently received chemotherapy alone, to which he had a complete response.
  • Fourteen additional patients were treated with 18 chemotherapy regimens.
  • There were two partial responses, eight stable disease, seven progressive disease and one allergic reaction precluding further treatment.
  • The overall response rate to any chemotherapy was 3/15 (20%, 95% CI 0.07-0.45), and the best overall response rate to chemotherapy with or without chest radiotherapy was 4/18 (22%, 95% CI 0.09-0.45).
  • CONCLUSIONS: Patients with typical and atypical pulmonary carcinoid tumors can respond to chemotherapy with or without chest radiotherapy, though with response rates that appear less than those of small cell lung cancers.
  • Further characterization of pulmonary carcinoid tumors and study of treatment alternatives for unresectable disease is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / drug therapy. Carcinoid Tumor / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15084386.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


25. O'Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP: Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy; 2001;47 Suppl 2:78-108
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin, its receptors and analogs, in lung cancer.
  • Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America.
  • Due to increasing cigarette consumption, the incidence of the disease and resultant mortality is rising dramatically in women.
  • Novel approaches to the management of lung cancer are urgently required.
  • Somatostatin is a tetradecapeptide first identified in the pituitary and subsequently throughout the body particularly in neuroendocrine cells of the pancreas and gastrointestinal tract and the nervous system.
  • Although elevated plasma somatostatin levels may be detected in 14-15% of patients, tumor cell expression appears rare.
  • SSTR may be expressed by lung tumors, particularly small cell lung cancer and bronchial carcinoid disease.
  • [(111)In]pentetreotide scintigraphy may have a role to play in the localization and staging of lung cancers both before and following treatment, and in detecting relapsed disease.
  • The potential role of radiolabelled somatostatin analogs as radiotherapeutic agents in the management of lung cancer is currently being explored.
  • Somatostatin analog therapy results in significant growth inhibition of both SSTR-positive and SSTR-negative lung tumors in vivo.
  • Recent work indicates that these agents may enhance the efficacy of chemotherapeutic agents in the treatment of solid tumors including lung cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / drug therapy. Receptors, Somatostatin / metabolism. Somatostatin / therapeutic use
  • [MeSH-minor] Humans. Radionuclide Imaging. Radiopharmaceuticals / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel.
  • (PMID = 11275704.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin
  • [Number-of-references] 181
  •  go-up   go-down


26. Kurabayashi T, Minamikawa T, Nishijima S, Tsuneki I, Tamura M, Yanase T, Hashidate H, Shibuya H, Motoyama T: Primary strumal carcinoid tumor of the ovary with multiple bone and breast metastases. J Obstet Gynaecol Res; 2010 Jun;36(3):567-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary strumal carcinoid tumor of the ovary with multiple bone and breast metastases.
  • Although primary carcinoid tumor of the ovary is an extremely rare neoplasm, survival is excellent if the disease is confined to one ovary.
  • Herein, we present a case of primary strumal carcinoid tumor of the ovary, stage IA, borderline malignancy, in a 34-year-old woman.
  • Histological findings of the right ovary indicated higher atypical nuclei, higher mitotic rate and focal necrosis of tumorous cells in some areas, findings that are compatible with atypical carcinoid of the lung.
  • Three and a half years postoperatively, multiple bone and breast metastases were found and anticancer chemotherapy was ineffective.
  • The results in the present case indicate that an ovarian carcinoid tumor found to be 'atypical carcinoid' according to pulmonary carcinoid criteria or immunohistochemical staining (i.e. highly positive for topoisomerase IIalpha and Ki-67) may have a poor prognosis.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / secondary. Carcinoid Tumor / secondary. Ovarian Neoplasms / pathology. Struma Ovarii / secondary


27. Kawase A, Nagai K: [Treatment strategy for neuroendocrine carcinoma of the lung]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1619-22
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment strategy for neuroendocrine carcinoma of the lung].
  • Neuroendocrine carcinoma of the lung is classified into typical carcinoid (TC), atypical carcinoid (ATC), large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCLC).
  • The standard treatment of carcinoid tumor is surgical resection.
  • There is no standard therapy for LCNEC.
  • Generally, the treatment of LCNEC is surgical resection and postoperative adjuvant chemotherapy in stage I and II, concurrent chemo-radiotherapy in stage III, and combination chemotherapy in stage IV.
  • The treatment of SCLC is mainly combination chemotherapy.
  • Standard therapy of SCLC is concurrent chemo-radiotherapy in limited disease and combination chemotherapy in extensive disease.
  • Combination chemotherapy with cisplatin and etoposide is administered for limited disease, and cisplatin and irinotecan is administered for extensive disease.
  • Adjuvant chemotherapy is needed postoperatively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Neuroendocrine / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838019.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Filosso PL, Croce S, Oliaro A, Ruffini E: Long-term survival of patients treated with octreotide for metastatic well differentiated neuroendocrine carcinoma of the lung. J Cardiovasc Surg (Torino); 2000 Oct;41(5):773-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of patients treated with octreotide for metastatic well differentiated neuroendocrine carcinoma of the lung.
  • Two patients with a radically operated well differentiated neuroendocrine carcinoma (WDNC) of the lung who developed a carcinoid syndrome due to metastatic spread of the tumor are reported.
  • Treatment with somatostatin analogue octreotide was administered to both patients following their refusal of a standard chemotherapic regimen.
  • Prompt resolution of the carcinoid syndrome was observed in both following octreotide treatment and both patients are alive and well after more than four years without evidence of further progression of the tumor.
  • It is suggested that octreotide should be considered as an effective therapy in WDNC for the control of the disease and associated paraneoplastic syndromes.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Neuroendocrine / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Octreotide / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149647.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


29. Hastings RH, Burton DW, Nefzi A, Montgrain PR, Quintana R, Deftos LJ: Combinatorial library discovery of small molecule inhibitors of lung cancer proliferation and parathyroid hormone-related protein expression. Cancer Biol Ther; 2010 Nov 15;10(10):1067-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combinatorial library discovery of small molecule inhibitors of lung cancer proliferation and parathyroid hormone-related protein expression.
  • PTHrP (parathyroid hormone-related protein) is abnormally expressed in a substantial majority of lung cancers, especially non-small cell lung cancers, and plays a key role in tumor progression.
  • Thus, this oncoprotein could be a target for treating patients with lung cancer.
  • Two libraries of over 780,000 bis-cyclic thiourea and guanidine compounds each were tested in BEN lung carcinoma cells.
  • Selected lead thiourea compounds decreased cell PTHrP protein content in dose-dependent fashion, reduced relative abundance of PTHrP mRNA, decreased transcripts derived from the PTHrP P3 promoter and reduced activity of a full length PTHrP promoter luciferase construct.
  • Similar effects on PTHrP mRNA were observed in A549 and H441 lung adenocarcinoma cells and in H727 lung carcinoid cells.
  • The compounds reduced the rate of cell proliferation in BEN cells and H727 cells, but not in lines that showed no inhibition of PTHrP protein.
  • These results suggest that cyclic thiourea compounds inhibit PTHrP expression mediated by the P3 promoter, which is widely used in the majority of PTHrP-expressing cells, and that they may inhibit growth of lung cancer cells through the same mechanism.
  • Further work will be necessary to investigate their mechanism for effects on growth of PTHrP-positive tumors in vivo.
  • [MeSH-major] Cell Proliferation / drug effects. Combinatorial Chemistry Techniques. Lung Neoplasms / drug therapy. Parathyroid Hormone-Related Protein / antagonists & inhibitors. Peptides, Cyclic / chemistry. Peptides, Cyclic / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Blotting, Western. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Humans. Luciferases / metabolism. Promoter Regions, Genetic. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890111.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 0 / Peptides, Cyclic; 0 / RNA, Messenger; EC 1.13.12.- / Luciferases
  •  go-up   go-down


30. Higashi K, Matsunari I, Ueda Y, Ikeda R, Guo J, Oguchi M, Tonami H, Yamamoto I: Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med; 2003 Feb;17(1):1-14
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of whole-body FDG PET in management of lung cancer.
  • FDG PET imaging is sensitive to the detection of lung cancer in patients who have indeterminate lesions on CT, whereas low grade malignancy such as bronchioloalveolar carcinoma and carcinoid may be negative on FDG PET.
  • This possibility should be kept in mind in the analysis of PET studies of glucose metabolism aimed at differentiating malignant from benign solitary pulmonary nodules.
  • FDG uptake is considered to be a good marker of cell differentiation, proliferative potential, aggressiveness, and the grade of malignancy in patients with lung cancer.
  • FDG PET accurately stages the distribution of lung cancer.
  • Several studies have documented the increased accuracy of PET compared with CT in the evaluation of the hilar and mediastinal lymphnode status in patients with lung cancer.
  • Whole-body PET studies detect metastatic disease that is unsuspected by conventional imaging.
  • Management changes have been reported in up to 41% of patients on the basis of the results of whole-body studies.
  • Whole-body FDG PET is also useful for the detection of recurrence.
  • Several studies have indicated that the degree of FDG uptake in primary lung cancer can be used as an independent prognostic factor.
  • Thus, whole-body FDG PET is clinically very useful in the management of lung cancer.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Neoplasm Recurrence, Local / diagnosis. Tomography, Emission-Computed / methods. Whole-Body Counting / methods
  • [MeSH-minor] Drug Therapy, Computer-Assisted / methods. Humans. Neoplasm Staging / methods. Radiopharmaceuticals / pharmacokinetics. Radiotherapy Planning, Computer-Assisted / methods. Reproducibility of Results. Sensitivity and Specificity. Solitary Pulmonary Nodule / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12691125.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 107
  •  go-up   go-down


31. Baltayiannis N, Bolanos N, Anagnostopoulos D, Sfyridis P, Georgiannakis E, Zografos P, Chatzimichalis A: Surgery in small cell lung cancer: when and why. J BUON; 2005 Oct-Dec;10(4):459-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery in small cell lung cancer: when and why.
  • Small cell lung cancer (SCLC) is considered a systemic disease at diagnosis, because the potential for hematogenous and lymphogenic metastases is very high.
  • For many years, the diagnosis of SCLC was considered a contraindication for surgery because radiotherapy was at least equivalent in terms of local control, and the rate of resectability in SCLC patients was poor.
  • When chemotherapy became the mainstay of treatment for SCLC, radiotherapy was its logical complement, and surgery was progressively abandoned.
  • However, some centers continued to support surgery because experience suggested that in selected patients it was possible to achieve a long-term survival.
  • In the search for predictors of long-term survival it became evident that the TNM staging system was effective for SCLC.
  • The rationale for surgery in the context of SCLC is based on 3 factors: a) Several historical series of patients operated for limited-stage SCLC reported some long-term survivors, showing that cure could be achieved.
  • b) After chemotherapy and radiotherapy, the rate of local relapse is 20%-30%.
  • The assumption that surgical resection might be superior for local disease control has been suggested but not yet proved.
  • c) The surgical intervention can precisely assess pathological (p) response to chemotherapy, identify carcinoids erroneously diagnosed as SCLC, and treat the non-small cell lung cancer (NSCLC) component of tumors with a mixed histology.
  • Even if some controversies exist, it is accepted that surgery can be proposed as the first treatment in patients with T1 or T2 lesions with no evidence of lymph node involvement, followed by adjuvant chemotherapy.
  • In more advanced stages of disease, chemotherapy should be the first step of treatment and surgery can be proposed to responding patients, before radical radiotherapy, depending on the p-stage of disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357202.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


32. Terzolo M, Reimondo G, Alì A, Bovio S, Daffara F, Paccotti P, Angeli A: Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Ann Oncol; 2001;12 Suppl 2:S83-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are roughly two types of ectopic ACTH syndrome (EAS).
  • The prototype of the first condition is Cushing's syndrome sustained by small-cell lung cancer (SCLC), while bronchial carcinoid tumors are the most common occult sources of ACTH.
  • These patients have a poor prognosis because SCLC associated with the EAS is more resistant to chemotherapy and the severe hypercortisolism is responsible for a high rate of life-threatening complications during treatment.
  • Conversely, the clinical and biochemical features of the EAS associated with carcinoid may overlap those seen in pituitary-dependent Cushing's syndrome.
  • Molecular biology studies have demonstrated that the carcinoid cells achieve a process of corticotroph differentiation being able to express the proopiomelanocortin (POMC) gene and to process POMC correctly to release large amounts of intact ACTH.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11762358.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 66796-54-1 / Pro-Opiomelanocortin
  • [Number-of-references] 25
  •  go-up   go-down


33. Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A: Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects. Pituitary; 2006;9(3):221-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
  • Hypothalamic GHRH is secreted into the portal system, binds to specific surface receptors of the somatotroph cell and elicits intracellular signals that modulate pituitary GH synthesis and/or secretion.
  • Moreover, GHRH is synthesized and expressed in multiple extrapituitary tissues.
  • Excessive peripheral production of GHRH by a tumor source would therefore be expected to cause somatotroph cell hyperstimulation, increased GH secretion and eventually pituitary acromegaly.
  • Immunoreactive GHRH is present in several tumors, including carcinoid tumors, pancreatic cell tumors, small cell lung cancers, endometrial tumors, adrenal adenomas, and pheochromocytomas which have been reported to secrete GHRH.
  • Dynamic pituitary tests are not helpful in distinguishing acromegalic patients with pituitary tumors from those harbouring extrapituitary tumors.
  • Plasma GHRH levels are usually elevated in patients with peripheral GHRH-secreting tumors, and are normal or low in patients with pituitary acromegaly.
  • Unique and unexpected clinical features in an acromegalic patient, including respiratory wheezing or dyspnea, facial flushing, peptic ulcers, or renal stones sometimes are helpful in alerting the physician to diagnosing non pituitary endocrine tumors.
  • Surgical resection of the tumor secreting ectopic GHRH should be the logical approach to a patient with ectopic GHRH syndrome.
  • Standard chemotherapy directed at GHRH-producing carcinoid tumors is generally unsuccessful in controlling the activated GH axis.
  • Somatostatin analogs provide an effective option for medical management of carcinoid patients, especially those with recurrent disease.
  • In fact, long-acting somatostatin analogs may be able to control not only the ectopic hormonal secretion syndrome, but also, in some instances, tumor growth.
  • Therefore, although cytotoxic chemotherapy, pituitary surgery, or irradiation still remain available therapeutic options, long-acting somatostatin analogs are now preferred as a second-line therapy in patients with carcinoid tumors and ectopic GHRH-syndrome.
  • [MeSH-major] Acromegaly / etiology. Adenoma / secretion. Carcinoid Tumor / secretion. Growth Hormone-Releasing Hormone / secretion. Growth Hormone-Secreting Pituitary Adenoma / secretion. Neuroendocrine Tumors / secretion. Paraneoplastic Endocrine Syndromes / etiology
  • [MeSH-minor] Animals. Biomarkers, Tumor / blood. Diagnosis, Differential. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / metabolism. Treatment Outcome. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):539-51 [1521511.001]
  • [Cites] Endocrinology. 1997 Nov;138(11):4543-51 [9348176.001]
  • [Cites] Eur J Endocrinol. 2005 Dec;153(6):737-40 [16322377.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):343-53 [2820064.001]
  • [Cites] Biochem Biophys Res Commun. 1982 Nov 16;109(1):152-8 [7159418.001]
  • [Cites] Endocrinology. 1985 Aug;117(2):457-67 [2862007.001]
  • [Cites] Endocr J. 1993 Feb;40(1):133-9 [7951487.001]
  • [Cites] J Endocrinol Invest. 1993 Sep;16(8):585-90 [8258646.001]
  • [Cites] Nature. 1983 Feb 17-23;301(5901):607-8 [6402707.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):717-97 [9861545.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] Metabolism. 1991 May;40(5):519-23 [2023538.001]
  • [Cites] Domest Anim Endocrinol. 1997 Sep;14(5):358-66 [9347256.001]
  • [Cites] J Neurosci. 1996 Dec 15;16(24):8140-8 [8987839.001]
  • [Cites] J Endocrinol Invest. 2003 Feb;26(2):163-9 [12739745.001]
  • [Cites] Nature. 1983 Jun 9-15;303(5917):532-5 [6406907.001]
  • [Cites] J Clin Endocrinol Metab. 1984 May;58(5):796-803 [6423659.001]
  • [Cites] J Clin Endocrinol Metab. 1989 May;68(5):917-24 [2565913.001]
  • [Cites] Proc Soc Exp Biol Med. 1990 Mar;193(3):232-5 [2106141.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] J Neuroendocrinol. 1989 Apr 1;1(2):109-15 [19210467.001]
  • [Cites] Endocrinology. 1976 Mar;98(3):580-9 [177264.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Mar;54(3):301-7 [11298081.001]
  • [Cites] Neuroendocrinology. 1990 May;51(5):572-5 [1693757.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3321-6 [7593445.001]
  • [Cites] Metabolism. 1990 Sep;39(9 Suppl 2):40-2 [1976218.001]
  • [Cites] N Engl J Med. 1990 Aug 2;323(5):322-7 [2164153.001]
  • [Cites] Endocrinology. 1984 Nov;115(5):2032-4 [6436012.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2797-802 [12788890.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Aug;59(2):197-201 [6330151.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1210-9 [9100598.001]
  • [Cites] Endocrinology. 1993 Sep;133(3):1029-34 [8103446.001]
  • [Cites] Pharmacol Res. 1996 Nov-Dec;34(5-6):247-68 [9076850.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Nov;59(5):846-9 [6434585.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):221-6 [2891432.001]
  • [Cites] Metabolism. 1992 Dec;41(12):1291-4 [1281259.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Endocrinol Jpn. 1989 Apr;36(2):229-36 [2550207.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):180-5 [2491860.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):43-54 [6243140.001]
  • [Cites] Physiol Rev. 1999 Apr;79(2):511-607 [10221989.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):22-8 [2491864.001]
  • [Cites] Clin Endocrinol (Oxf). 1987 Sep;27(3):297-306 [2892599.001]
  • [Cites] FEBS Lett. 1996 Sep 23;394(1):1-4 [8925914.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Mar;64(3):585-91 [3102543.001]
  • [Cites] Endocrinology. 1985 Jul;117(1):424-6 [2988927.001]
  • [Cites] J Endocrinol Invest. 2003;26(8 Suppl):4-7 [15233203.001]
  • [Cites] Nature. 1982 Nov 18;300(5889):276-8 [6292724.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):17-24 [1973173.001]
  • [Cites] Endocrinology. 1972 Oct;91(4):1071-8 [5051331.001]
  • [Cites] J Endocrinol Invest. 2003 Dec;26(12):1242-7 [15055479.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):43-7 [16625844.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] Endocrinology. 1984 Apr;114(4):1082-5 [6423368.001]
  • [Cites] Endocrinology. 1992 Mar;130(3):1097-102 [1537276.001]
  • [Cites] Clin Endocrinol (Oxf). 1986 Feb;24(2):135-40 [2871948.001]
  • [Cites] Nature. 1983 Nov 3-9;306(5938):84-5 [6415487.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] Nature. 1985 Mar 21-27;314(6008):279-81 [2858817.001]
  • [Cites] Endocrinology. 1985 Oct;117(4):1598-601 [3928335.001]
  • [Cites] Lancet. 1984 Aug 18;2(8399):401-2 [6147476.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] Endocrinology. 1983 Nov;113(5):1726-31 [6194979.001]
  • [Cites] Nature. 1993 Jul 15;364(6434):208-13 [8391647.001]
  • [Cites] Eur J Endocrinol. 1995 Jan;132(1):12-24 [7850005.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Eur J Endocrinol. 1998 Jul;139(1):59-71 [9703380.001]
  • [Cites] Clin Endocrinol (Oxf). 1976 Sep;5(5):503-13 [991433.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4054-8 [12213843.001]
  • [Cites] Science. 1982 Nov 5;218(4572):585-7 [6812220.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Apr;30(4):367-77 [2574645.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1326-31 [8625907.001]
  • [Cites] Endocr Rev. 1986 Aug;7(3):223-53 [2874984.001]
  • [Cites] Am J Med. 1984 Apr;76(4):605-16 [6424465.001]
  • [Cites] Science. 1975 Feb 7;187(4175):447-9 [1111113.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Feb;60(2):370-5 [3917460.001]
  • [Cites] Cancer. 1991 May 15;67(10):2538-42 [2015554.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Oct;128(4):631-2 [15457172.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3989-95 [11502843.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Adv Tech Stand Neurosurg. 1995;22:3-53 [7495421.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Oct;59(4):747-51 [6434578.001]
  • [Cites] Annu Rev Med. 1990;41:447-55 [2184742.001]
  • [Cites] J Endocrinol Invest. 1993 Jan;16(1):69-81 [8445159.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Apr 12;292(6526):981-2 [2870758.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Jan;58(1):212-4 [6417155.001]
  • [Cites] Science. 1985 Oct 25;230(4724):461-3 [2864742.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1734-44 [1333056.001]
  • [Cites] Eur J Endocrinol. 1997 Jun;136(6):553-65 [9225715.001]
  • [Cites] Ir J Med Sci. 2004 Oct-Dec;173(4):215-6 [16323617.001]
  • [Cites] Acta Endocrinol (Copenh). 1985 May;109(1):13-8 [3923754.001]
  • [Cites] Endocrinology. 1991 Feb;128(2):1151-8 [1671214.001]
  • [Cites] J Endocrinol Invest. 1994 Oct;17(9):717-22 [7868816.001]
  • [Cites] Brain Res. 1989 Feb 27;481(1):8-15 [2565134.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • [Cites] Endocrinology. 1985 Apr;116(4):1334-40 [3918850.001]
  • (PMID = 17036195.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 9034-39-3 / Growth Hormone-Releasing Hormone
  • [Number-of-references] 101
  •  go-up   go-down


34. Bednaríková M, Valík D, Vyzula R: [Somatostatin analogues in the treatment of carcinoid]. Cas Lek Cesk; 2008;147(4):233-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Somatostatin analogues in the treatment of carcinoid].
  • The patient--born in 1960, was first diagnosed in 1981 as having malignant carcinoid of the right lung.
  • The disease relapsed in 2002 in a form of distant dissemination.
  • According to tumor histology--atypical carcinoid--this patient was initially treated with palliative systemic chemotherapy, specifically with cisplatin and etoposid.
  • His disease stabilized after administration of 4 cycles of chemotherapy.
  • The treatment was accompanied by protracted toxicity with marked alteration of his general conditions after the 4th cycle.
  • Due to positive octreoscan, the patient was given somatostatin analogues with a very good and long-term clinical effect.
  • The symptoms disappeared, except a persisting ocular disorder due to periorbital infiltration.
  • The patient has been still (with two 5,5 years interruptions) treated with somatostatin analogues with very good tolerance and clinical effect--at present there are no symptoms of the disease and, according to imaging methods, long-term stabilization continues.
  • This case study illustrates the necessity of cautious and individual approach to the choice of treatment strategy in patients with malignant carcinoid.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoid Tumor / drug therapy. Lung Neoplasms / pathology. Somatostatin / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18578378.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 51110-01-1 / Somatostatin
  •  go-up   go-down


35. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O: Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg; 2002 May;21(5):913-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
  • OBJECTIVE: To demonstrate that liver metastases by radically resected atypical carcinoids of the lung can be effectively treated by new somatostatin analogs.
  • METHODS: Between January 1977 and December 1999, 126 patients affected by bronchial carcinoids were submitted to a radical resection of the lung.
  • Seven of them (5.5%) presented liver metastases 27, 22, 14, 18, 16, 12 and 9 months after surgery: carcinoid syndrome (CS) was ever present.
  • RESULTS: Five patients refused the proposed chemotherapy, and liver alcoholization was not feasible.
  • CS was controlled and also high urinary 5-hydroxyindoleacetic acid values returned to normal after a median of 7 days (range 4-10 days) of medical treatment.
  • The patients are alive and well at 51, 36, 24, 24, 23, 19, and 16 months after the diagnosis of the metastases, respectively.
  • CONCLUSIONS: Octreotide is effective in controlling symptoms of CS of patients with liver metastases of resected atypical bronchial carcinoid.
  • The efficacy of the drug is due to the presence of sst2 somatostatin receptors in the pathologic tissue, as demonstrated by PCR method.
  • Octreoscan may be used in the follow-up of these neuroendocrine neoplasms of the lung.
  • A positivity to Octreoscan is predictive for an effective therapy with octreotide.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Bronchial Neoplasms / pathology. Carcinoid Tumor / drug therapy. Liver Neoplasms / drug therapy. Octreotide / therapeutic use
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Postoperative Care. Somatostatin / analogs & derivatives. Survival Rate

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12062286.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 51110-01-1 / Somatostatin; G083B71P98 / pentetreotide; RWM8CCW8GP / Octreotide
  •  go-up   go-down


36. Pelosi G, Masullo M, Leon ME, Veronesi G, Spaggiari L, Pasini F, Sonzogni A, Iannucci A, Bresaola E, Viale G: CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. Virchows Arch; 2004 Nov;445(5):449-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas.
  • Little is known about CD117 prevalence and clinicopathological implications in pulmonary large-cell neuroendocrine carcinoma.
  • We studied CD117 immunoreactivity in surgical specimens from 39 large-cell neuroendocrine carcinomas of stages I-III and 27 limited-disease small-cell carcinomas, 56 typical and atypical carcinoids of the lung, and 10 neuroendocrine tumorlets, including the membrane and cytoplasmic immunostaining patterns.
  • Membrane CD117 immunoreactivity in 5% or more tumor cells was documented in 30 (77%) large-cell neuroendocrine carcinomas and 18 (67%) small-cell carcinomas and 4 (7%) carcinoids, whereas cytoplasmic labeling was seen in 17 (44%) large-cell neuroendocrine carcinomas, 19 (70%) small-cell carcinomas, and 3 (5%) carcinoids.
  • Cytoplasmic immunostaining was more prevalent in small-cell carcinomas, whereas membrane labeling did not differ between the two types of high-grade carcinomas.
  • Downregulation of CD117 by neoadjuvant chemotherapy was seen in large-cell neuroendocrine carcinomas but not small-cell carcinomas.
  • Multiple linear regression analysis demonstrated a marginal association between cytoplasmic CD117 immunoreactivity and regional lymph node metastasis in small-cell carcinomas but not large-cell neuroendocrine carcinomas.
  • [MeSH-major] Carcinoma, Small Cell / chemistry. Lung Neoplasms / chemistry. Neuroendocrine Tumors / chemistry. Proto-Oncogene Proteins c-kit / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):934-44 [9706973.001]
  • [Cites] Methods Mol Med. 2003;74:113-25 [12415690.001]
  • [Cites] Genes Chromosomes Cancer. 2000 May;28(1):58-65 [10738303.001]
  • [Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):49-56 [10937049.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1182-7 [12514786.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Mar;11(1):51-5 [12610357.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Oncogene. 2000 Jul 20;19(31):3521-8 [10918610.001]
  • [Cites] Ann Thorac Surg. 2004 Jan;77(1):247-52; discussion 252-3 [14726070.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]
  • [Cites] Int J Cancer Suppl. 1994;8:108-9 [7515024.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):894-7 [12796027.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1041-7 [14559988.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):711-21 [15073598.001]
  • [Cites] J Pathol. 2002 Sep;198(1):100-9 [12210069.001]
  • [Cites] JAMA. 1965 Jul 5;193:52-4 [14297714.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):188-94 [12538468.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):317-23 [10760691.001]
  • [Cites] Hum Pathol. 1998 May;29(5):498-504 [9596274.001]
  • [Cites] Genes Chromosomes Cancer. 2002 May;34(1):78-85 [11921285.001]
  • [Cites] Lung Cancer. 2003 May;40(2):173-80 [12711118.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Cell. 1990 Oct 5;63(1):5-6 [2208282.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1037-51 [10582338.001]
  • [Cites] Am J Pathol. 1993 Jan;142(1):339-46 [7678721.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):370-6 [8542594.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1551-8 [14657715.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2416-9 [1707753.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1059-63 [11679939.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5825-8 [14676102.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):272-9 [9496831.001]
  • (PMID = 15375659.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


37. Srirajaskanthan R, Toumpanakis C, Karpathakis A, Marelli L, Quigley AM, Dusmet M, Meyer T, Caplin ME: Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung Cancer; 2009 Jul;65(1):68-73
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients.
  • Bronchial neuroendocrine tumours account for 1-2% of all lung cancers; they are thought to arise from the neuroendocrine cells located in the bronchial mucosa.
  • The majority of the literature available comprises surgical series and there is a scarcity of data available for the management of patients with inoperable disease.
  • We present a series of 45 patients referred to our institution from 1998 to 2006, with a mean follow-up of 54 months.
  • Histological diagnosis from our department was available for 39 patients, with the remainder having had histological assessment performed previously.
  • Typical carcinoid was present in 25 cases, atypical in 9 cases, large cell neuroendocrine carcinoma in 4 and 1 case of small cell lung carcinoma.
  • All patients were staged at time of initial diagnosis with CT scan, in addition Octreoscans were performed when appropriate.
  • Twenty-six of these 45 cases had unresectable disease, whilst the remainder were treated with surgical resection.
  • Initial therapy with surgical resection was performed in 19 patients, 2 of whom had undergone neo-adjuvant chemotherapy.
  • Recurrence occurred in 7 (36.8%), average duration of disease-free survival post-surgery was 61 months.
  • Chemotherapy was first line therapy in five cases, four achieved disease stabilization and one case had progressive disease.
  • Somatostatin analogues were used as first line therapy in six patients, for symptom control and anti-tumour effect.
  • Peptide receptor radionuclide therapy, with Yttrium-90 DOTA-Octreotate, was given in two cases, both of whom achieved disease stabilization for 9-12 months respectively.
  • There was a significant difference between Stage 4 and Stage 1 disease at presentation and survival.
  • In conclusion curative surgical resection is treatment of choice, however, chemotherapy, somatostatin analogues and peptide receptor radionuclide therapy offers palliation improving both symptoms and mortality.
  • [MeSH-major] Bronchial Neoplasms / therapy. Carcinoid Tumor / therapy. Palliative Care / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19070398.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  •  go-up   go-down


38. Oberg K: Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol; 2001;12 Suppl 2:S111-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
  • The medical treatment of neuroendocrine GEP tumours must be based on the growth properties of the tumour.
  • Medical treatment includes chemotherapy, somatostatin analogues and alpha interferons.
  • Chemotherapy has been particularly active in patients with high proliferating neuroendocrine tumours such as endocrine pancreatic tumours and lung carcinoids.
  • Streptozotocin-based combinations including 5-flourouracil and doxorubicin have generated partial remissions in 40%-60% of the patients giving a median survival of about two years in patients with advanced disease.
  • Cisplatinum plus etoposide have demonstrated significant antitumour effects in anaplastic endocrine pancreatic tumours and lung carcinoids.
  • However, in low proliferating tumours such as classical midgut carcinoids the response rates with the same combinations of cytotoxic agents have only generated short lasting responses in less than 10% of patients.
  • In these patients, biological treatment has been of benefit.
  • Alpha interferon at doses of 3-9 million units three to seven times per week subcutaneously, has given biochemical response rates of 50% and significant tumour reduction in about 15% of patients with long duration, up to three years.
  • Somatostatin analogues have been widely used in the treatment of neuroendocrine gut and pancreatic tumours.
  • Octreotide is registered in most countries for the treatment of patients with carcinoid syndrome and also VIP and glucagon producing tumours.
  • Significant tumour responses are rare, less than 5%.
  • Long-acting formulations of somatostatin analogues have been of significant benefit for the patients with similar response rates as for regular formulations.
  • The quality of life has been significantly improved by using the long-acting formulations.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11762335.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Interferon-alpha; 0 / Peptides, Cyclic; 0 / Receptors, Somatostatin; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 5W494URQ81 / Streptozocin; Q20Q21Q62J / Cisplatin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 23
  •  go-up   go-down


39. Gilbert JA, Frederick LM, Pobst LJ, Ames MM: Hydrogen peroxide degradation and selective carbidopa-induced cytotoxicity against human tumor lines. Biochem Pharmacol; 2005 Apr 15;69(8):1159-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydrogen peroxide degradation and selective carbidopa-induced cytotoxicity against human tumor lines.
  • The carcinoid tumor, an uncommon neuroendocrine neoplasm, is associated with serotonin overproduction as is more common small cell lung carcinoma (SCLC).
  • alpha-Methyl-dopahydrazine (carbidopa), an inhibitor of the serotonin synthetic enzyme aromatic-L-amino acid decarboxylase, proved lethal to NCI-H727 lung carcinoid cells as well as NCI-H146 and NCI-H209 SCLC cells, but not to five other human tumor cell lines of differing origins [Gilbert JA, Frederick LM, Ames MM.
  • The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin.
  • Alkaline elution studies revealed carbidopa-dependent single-strand DNA breaks in sensitive carcinoid cells comparable to those induced by similar concentrations of H2O2.
  • Neither compound induced significant DNA damage in carbidopa-resistant NCI-H460 large cell lung carcinoma cells.
  • Furthermore, when carbidopa was incubated with a variety of tumor cell types, not only were decreased media H2O2 concentrations detected in the presence of cells, but cell lines least sensitive to carbidopa degraded exogenous H2O2 more rapidly than did sensitive cells.
  • Implicated in these studies, pyruvate degraded H2O2 in RPMI in a dose- and time-dependent manner and reversed carbidopa-induced cytotoxicity to carcinoid cells.
  • Extracellular pyruvate levels produced per h by resistant large cell lung carcinoma cells averaged four-fold that of sensitive carcinoid cells plated at equal density (24 h time course).
  • Finally, carbidopa exposure (100 microM, 24 h) depleted extracellular pyruvate from sensitive carcinoid cells, but reduced pyruvate levels from resistant NCI-H460 cells less than 17%.
  • [MeSH-major] Aromatic Amino Acid Decarboxylase Inhibitors. Carbidopa / toxicity. Carcinoid Tumor / drug therapy. Carcinoma, Small Cell / drug therapy. Hydrogen Peroxide / metabolism. Lung Neoplasms / drug therapy
  • [MeSH-minor] Cell Survival / drug effects. Culture Media / chemistry. Culture Media / metabolism. Dose-Response Relationship, Drug. Humans. Kinetics. Oxidation-Reduction. Pyruvic Acid / metabolism. Pyruvic Acid / pharmacology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794936.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aromatic Amino Acid Decarboxylase Inhibitors; 0 / Culture Media; 8558G7RUTR / Pyruvic Acid; BBX060AN9V / Hydrogen Peroxide; MNX7R8C5VO / Carbidopa
  •  go-up   go-down


40. Nakamura Y, Okada Y, Endo C, Aikawa H, Sakurada A, Sato M, Kondo T: Endobronchial carcinoid tumor combined with pulmonary non-tuberculous mycobacterial infection: report of two cases. Lung Cancer; 2003 Feb;39(2):227-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial carcinoid tumor combined with pulmonary non-tuberculous mycobacterial infection: report of two cases.
  • We report here two cases of endobronchial carcinoid tumor complicated with pulmonary infection with non-tuberculous mycobacteria (NTM).
  • Bronchoscopy showed complete obstruction of the left basal bronchus by a tumor and a sleeve lower lobectomy with mediastinal lymph node dissection was performed.
  • Pathological examination showed typical carcinoid located in the left basal bronchus and many caseous granulomas containing mycobacteria in the lung parenchyma distal to the bronchus.
  • Bronchoscopy showed complete obstruction of the left upper division bronchus by a tumor and a left upper lobectomy with mediastinal lymph node dissection was performed.
  • Pathological examination showed typical carcinoid located in the left upper division bronchus and many caseous granulomas in the lung parenchyma distal to the bronchus.
  • Although NTM are not well recognized as possible pathogens of pulmonary infection related to bronchial obstruction by endobronchial carcinoma, our experiences rouse a caution to consider NTM as potential pathogens.
  • We also discuss the possible mechanisms responsible for the specific relationship between carcinoid tumor and TNM.
  • [MeSH-major] Bronchial Neoplasms / complications. Carcinoid Tumor / complications. Mycobacterium avium Complex / isolation & purification. Mycobacterium avium-intracellulare Infection / complications. Mycobacterium kansasii / isolation & purification. Pneumonia, Bacterial / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Anti-Bacterial Agents. Bronchoscopy. Drug Therapy, Combination / therapeutic use. Female. Gastric Juice / microbiology. Humans. Lymph Nodes / pathology. Middle Aged. Sputum / microbiology

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science Ireland Ltd.
  • (PMID = 12581578.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


41. Bruno OD, Danilowicz K, Manavela M, Mana D, Rossi MA: Long-term management with octreotide or cabergoline in ectopic corticotropin hypersecretion: case report and literature review. Endocr Pract; 2010 Sep-Oct;16(5):829-34
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term management with octreotide or cabergoline in ectopic corticotropin hypersecretion: case report and literature review.
  • OBJECTIVE: To describe the corticotropin response to long-term octreotide or cabergoline administration in a patient with ectopic corticotropin secretion who underwent adrenalectomy.
  • On the basis of biochemical indices, Cushing disease was diagnosed and pituitary exploration was performed.
  • Computed tomography of the chest revealed a right lung nodule due to a lung carcinoid tumor that was then surgically excised.
  • Subsequently, corticotropin levels rose dramatically and hyperpigmentation developed while serum cortisol was in the reference range.
  • Cabergoline induced a similar long-lasting effect on the clinical and biochemical parameters observed.
  • Eight years later, she is still treated with cabergoline, and no lung tumor has been detected.
  • CONCLUSIONS: In this patient with ectopic Cushing syndrome, treatment with either octreotide or cabergoline markedly reduced corticotropin levels and hyperpigmentation.
  • [MeSH-major] ACTH Syndrome, Ectopic / drug therapy. Carcinoid Tumor / drug therapy. Carcinoid Tumor / secretion. Ergolines / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secretion. Octreotide / therapeutic use
  • [MeSH-minor] Adrenalectomy / adverse effects. Adrenalectomy / methods. Adrenalectomy / rehabilitation. Adrenocorticotropic Hormone / secretion. Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Time Factors

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497940.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ergolines; 9002-60-2 / Adrenocorticotropic Hormone; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide
  •  go-up   go-down


42. Hage R, Seldenrijk K, de Bruin P, van Swieten H, van den Bosch J: Pulmonary large-cell neuroendocrine carcinoma (LCNEC). Eur J Cardiothorac Surg; 2003 Apr;23(4):457-60
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pulmonary large cell neuroendocrine carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary large-cell neuroendocrine carcinoma (LCNEC).
  • OBJECTIVE: The experiences on the treatment of seven consecutive patients with large-cell neuroendocrine carcinoma (LCNEC) were studied, observed over 6 years from 1992.
  • Since LCNEC was recognized as a separate histological entity, only very few series have been reported.
  • Together with the carcinoids (atypical and typical) and the small-cell lung carcinoma (SCLC), it forms the spectrum of neuroendocrine tumors.
  • RESULTS: In five patients, preoperative diagnosis was unknown, in one squamous cell carcinoma and in one adenocarcinoma was suspected.
  • There were four lobectomies, two bilobectomies and one resection of the lingular division with a wedge resection of the upper division of the left upper lobe.
  • Three patients received adjuvant chemotherapy and one, adjuvant radiotherapy.
  • CONCLUSIONS: LCNEC is a high-grade neuroendocrine tumor with a poor prognosis.
  • In our patients, after surgical resection or multimodality treatment, all have developed widespread metastatic disease with a rapidly fatal course.
  • Due to the rarity of this tumor, the incidence, prognosis and optimal treatment remain to be determined.
  • [MeSH-major] Carcinoma, Large Cell / surgery. Carcinoma, Neuroendocrine / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2003 Oct;24(4):671-2; author reply 672-3 [14500107.001]
  • (PMID = 12694759.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 13
  •  go-up   go-down


43. Morandi U, Casali C, Rossi G: Bronchial typical carcinoid tumors. Semin Thorac Cardiovasc Surg; 2006;18(3):191-8
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchial typical carcinoid tumors.
  • The current WHO classification of lung tumors recognizes bronchial typical carcinoid as low-grade neuroendocrine tumors.
  • These tumors grow slowly but can metastasize to regional nodes (4 to 20%) and more rarely to extrathoracic sites.
  • Paraneoplastic syndrome can be present (carcinoid syndrome, Cushing's syndrome, acromegaly).
  • Preoperative diagnosis is usually obtained with bronchoscopic biopsy.
  • Computed tomography and somatostatin receptor scintigraphy are useful in the preoperative staging.
  • The complete surgical resection remains the only therapy with curative intent in the majority of patients.
  • Parenchyma-sparing resections are indicated whenever possible.
  • N-status and type of resection seem not to affect prognosis.
  • Local relapse can be treated successfully with surgery, whereas distant metastases have a poor prognosis even after chemotherapy.
  • [MeSH-major] Bronchial Neoplasms / pathology. Carcinoid Tumor / pathology. Neuroendocrine Tumors / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185178.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


44. Yesner R: Heterogeneity of so-called neuroendocrine lung tumors. Exp Mol Pathol; 2001 Jun;70(3):179-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of so-called neuroendocrine lung tumors.
  • The diagnosis of neuroendocrine (NE) lung tumor is dependent on a number of observations: organoid structure, dense core granules, and various molecular components, including chromogranin A, neurosecretory enolase, synaptophysin, neural cell adhesion molecules, and others.
  • None of these is specific for lung tumors.
  • The Kulchitsky cell, which has these characteristics, forms a carcinoid, which exemplifies the NE tumor.
  • It is euploid, has few mitoses, no necrosis and a 5- to 10-year survival of over 90%.
  • When carcinoids show malignant characteristics, i.e., increased mitoses and necrosis, they have been labeled atypical and have a survival of 50%.
  • Because all other non-small cell lung tumors, especially large cell tumors, may show one or more of these things because of the inherent heterogeneity of lung tumors, the term NE has been applied to them without real evidence that this affects survival with or without chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology. Neuroendocrine Tumors / classification. Neuroendocrine Tumors / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Chromogranin A. Chromogranins / analysis. Cytoplasmic Granules / pathology. Humans. Neural Cell Adhesion Molecules / analysis. Phosphopyruvate Hydratase / analysis. Synaptophysin / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11417996.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins; 0 / Neural Cell Adhesion Molecules; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 59
  •  go-up   go-down


45. Walther DJ, Peter JU, Bader M: 7-Hydroxytryptophan, a novel, specific, cytotoxic agent for carcinoids and other serotonin-producing tumors. Cancer; 2002 Jun 15;94(12):3135-40
Hazardous Substances Data Bank. (L)-Tryptophan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 7-Hydroxytryptophan, a novel, specific, cytotoxic agent for carcinoids and other serotonin-producing tumors.
  • BACKGROUND: Carcinoids and small cell lung carcinomas stimulate their growth in an autocrine manner by releasing serotonin, an effect that is blocked by selective serotonergic receptor antagonists that, unfortunately, exert undesirable side effects on serotonergic central nervous function.
  • Moreover, conventional chemotherapeutic agents, such as streptozocin, fluorouracil, cyclophosphamide, and doxorubicin, which target tumor cells directly, have produced disappointing results in the treatment of patients with these tumors in the advanced stage.
  • Therefore, there is still a need for more specific and potent chemotherapeutic agents in the fight against serotonin-producing tumors.
  • METHODS: The authors synthesized 7-hydroxytryptophan to test its chemotherapeutic value in cell culture, using a system consisting of serotonin-producing and nonproducing cell lines.
  • RESULTS: The authors chose tryptophan hydroxylase, the rate-limiting enzyme of serotonin biosynthesis, which is expressed highly in small cell lung carcinomas and carcinoids, as a target for the induction of cellular suicide by chemotherapy.
  • CONCLUSIONS: These data suggest that 7-hydroxytryptophan may be a highly specific chemotherapeutic compound against serotonin-producing tumors that also interferes with the autocrine capabilities of serotonin synthesis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoid Tumor / drug therapy. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Serotonin / biosynthesis. Tryptophan / pharmacology
  • [MeSH-minor] 5,6-Dihydroxytryptamine / pharmacology. 5,7-Dihydroxytryptamine / pharmacology. Animals. COS Cells. Humans. Pancreatic Neoplasms / drug therapy. Tryptophan Hydroxylase / antagonists & inhibitors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12115345.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 7-hydroxytryptophan; 0 / Antineoplastic Agents; 31363-74-3 / 5,7-Dihydroxytryptamine; 333DO1RDJY / Serotonin; 8DUH1N11BX / Tryptophan; EC 1.14.16.4 / Tryptophan Hydroxylase; W2QY253O8S / 5,6-Dihydroxytryptamine
  •  go-up   go-down


46. Zatelli MC, Maffei P, Piccin D, Martini C, Rea F, Rubello D, Margutti A, Culler MD, Sicolo N, degli Uberti EC: Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J Clin Endocrinol Metab; 2005 Apr;90(4):2104-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid.
  • A 29-yr-old woman presented with acromegaly, pituitary gland enlargement, and an isolated pulmonary mass of 3.3 cm in diameter, which displayed a very high tracer uptake after OctreoScan.
  • The patient underwent left lung upper lobectomy, and histopathology disclosed a bronchial atypical carcinoid.
  • The tissue was examined for somatostatin (SRIH) receptor subtypes (SSTRs) 1-5 expression by RT-PCR.
  • Cultured tumor cells were treated with SRIH, lanreotide (BIM-23014), or SRIH analogs selective for SSTR2 (BIM-23120), SSTR5 (BIM-23206), or SSTR1 (BIM-23926).
  • GHRH secretion was significantly reduced by SRIH (-50%), Lan (-35%), as well as by the SSTR2, SSTR5, and SSTR1 selective agonists (-55, -75, and -20%, respectively), whereas cell viability was not affected.
  • Our data show SSTR expression in a GHRH-secreting bronchial carcinoid and provide evidence that, in vitro, selective SSTR activation differently inhibit ectopic GHRH secretion.
  • These findings suggest that SSTR-specific SRIH analogs may be useful in the medical therapy of GHRH-secreting bronchial carcinoids.
  • [MeSH-major] Bronchial Neoplasms / drug therapy. Carcinoid Tumor / drug therapy. Growth Hormone-Releasing Hormone / secretion. Receptors, Somatostatin / agonists
  • [MeSH-minor] Adult. Cell Survival / drug effects. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671091.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 9034-39-3 / Growth Hormone-Releasing Hormone
  •  go-up   go-down


47. Pectasides D, Glotsos J, Bountouroglou NG, Dadioti PA, Athanassiou AE: Primary carcinoid of the testis with metastases. Case report and review of the literature. J BUON; 2002 Apr-Jun;7(2):153-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid of the testis with metastases. Case report and review of the literature.
  • Primary carcinoid of the testis is an extremely rare neoplasm, making up 0.23% of all testicular neoplasms.
  • The vast majority of the reported cases are primary carcinoids and 20-25% are associated with teratomas.
  • Approximately 10% of these tumors will develop metastases.
  • We present a case of a 50-year-old man with a primary testicular carcinoid who developed lymph node and lung metastases 4 months after left inguinal orchidectomy.
  • Our case was not associated with testicular teratoma or carcinoid syndrome.
  • Vigorous efforts were done postoperatively to exclude the possibility of carcinoid tumor metastatic to the testis.
  • Our patient achieved a mixed response (lung metastases: complete response, lymph node metastases: partial response) with combined therapy that included chemotherapy (cisplatin, etoposide, ifosfamide, epirubicin), octreotide and radiotherapy to the metastatic lymph nodes.
  • He remains well and asymptomatic.
  • We herein review the literature and discuss all the possibilities to explain the origin of carcinoid tumors of the testis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577281.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


48. Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, Smith WI Jr, Meltzer P, Wang Y, Giaccone G: Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A; 2010 Jul 20;107(29):13040-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.
  • The goal of this study was to characterize and classify pulmonary neuroendocrine tumors based on array comparative genomic hybridization (aCGH).
  • Using aCGH, we performed karyotype analysis of 33 small cell lung cancer (SCLC) tumors, 13 SCLC cell lines, 19 bronchial carcinoids, and 9 gastrointestinal carcinoids.
  • In contrast to the relatively conserved karyotypes of carcinoid tumors, the karyotypes of SCLC tumors and cell lines were highly aberrant.
  • High copy number (CN) gains were detected in SCLC tumors and cell lines in cytogenetic bands encoding JAK2, FGFR1, and MYC family members.
  • In some of those samples, the CN of these genes exceeded 100, suggesting that they could represent driver alterations and potential drug targets in subgroups of SCLC patients.
  • In SCLC tumors, as well as bronchial carcinoids and carcinoids of gastrointestinal origin, recurrent CN alterations were observed in 203 genes, including the RB1 gene and 59 microRNAs of which 51 locate in the DLK1-DIO3 domain.
  • These findings suggest the existence of partially shared CN alterations in these tumor types.
  • Finally, by analyzing potential drug targets, we provide a genomics-based rationale for targeting the AKT-mTOR and apoptosis pathways in SCLC.
  • [MeSH-major] Comparative Genomic Hybridization / methods. Lung Neoplasms / genetics. Neuroendocrine Tumors / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bronchial Neoplasms / drug therapy. Bronchial Neoplasms / genetics. Carcinoid Tumor / genetics. Cell Line, Tumor. Cytogenetic Analysis. DNA Copy Number Variations / genetics. Female. Gene Dosage / genetics. Gene Expression Regulation, Neoplastic. Genome, Human / genetics. Humans. Male. Middle Aged. Small Cell Lung Carcinoma / genetics


49. Daddi N, Ferolla P, Urbani M, Semeraro A, Avenia N, Ribacchi R, Puma F, Daddi G: Surgical treatment of neuroendocrine tumors of the lung. Eur J Cardiothorac Surg; 2004 Oct;26(4):813-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of neuroendocrine tumors of the lung.
  • OBJECTIVE: This report reviews the pattern of neuroendocrine (NE) differentiation, lymph-node involvement, extension of surgery, and survival in 125 NE lung tumor patients.
  • NE differentiation was assessed based on the morphology and immunohistochemical reactivity for pan-neuroendocrine markers NSE, CGA, and Synaptophysin.
  • RESULTS: There were 79 typical carcinoid (TC), eight atypical carcinoid (AC), 18 large cell carcinoma (LCC) and 20 SCC patients.
  • Mean age at diagnosis was 54.6+/-15.2 (ranges from 16 to 77 years) for TC, 68.5+/-9.1 (range 53-81) for AC, 68.7+/-4.6 (range 58-77) for LCC, 64.6+/-7.9 (range 48-82) for SCC.
  • Presenting symptoms were invariably of respiratory-related.
  • None had the carcinoid syndrome.
  • Survival ranged from a minimum of 1 month for SCC to a maximum of 168 months with no evidence of disease for TC.
  • Twenty-one percent (4/19) of the patients with SCC treated by induction therapy and surgery, and in few cases by surgery and adjuvant chemotherapy are alive without the evidence of the disease for 5 years.
  • CONCLUSIONS: Due to the high percentage of lymph-node involvement and multicentric forms found in our series lobectomy with radical lymph-node dissection appears, in our opinion, the most appropriate surgical treatment in well-differentiated forms, while more limited resection appears sub-optimal.
  • Also, due to the finding of recurrences many years after surgery, the follow-up must be accurate and protracted in this subgroup.
  • Only Small Cell Lung Carcinoma patients in clinical stage I and II underwent surgery with good long-term results.
  • [MeSH-major] Lung Neoplasms / surgery. Neuroendocrine Tumors / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / diagnosis. Carcinoid Tumor / secondary. Carcinoid Tumor / surgery. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Pneumonectomy / methods. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15450578.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Leo F, Pastorino U: Surgery in small-cell lung carcinoma. Where is the rationale? Semin Surg Oncol; 2003;21(3):176-81
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery in small-cell lung carcinoma. Where is the rationale?
  • Chemotherapy and radiotherapy are the keys of current management of SCLC.
  • For many years, the diagnosis of small cell lung cancer has been considered a contraindication to surgery because radiotherapy was at least equivalent in terms of local control and the rate of resectability of SCLC patients was poor.
  • 1) Several historical series on patients operated for limited SCLC reported some long term survivors, showing that permanent cure can be achieved.
  • For this reason, it is now accepted that for the rare patients with very limited stage disease (T1-T2 tumors) surgical resection followed by platinum-based chemotherapy could be offered.
  • 2) After chemotherapy and radiotherapy, the rate of local relapse is 20-30%.
  • The assumption that surgery might be superior to radiotherapy in local control of limited SCLC has been suggested but not still proved.
  • 3) Surgery can precisely assess pathological response to chemotherapy, identify carcinoids erroneously diagnosed as SCLC, treat the NSCLC component of tumors with a mixed histology.
  • Even if some controversies exist, it is accepted that surgery can be proposed as the first treatment in patents with T1-T2 lesions without sign of lymph nodes involvement, followed by adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Brain / pathology. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Patient Care Planning. Patient Selection. Preoperative Care. Prognosis. Thoracotomy. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14508850.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


51. Spaggiari L, D' Aiuto M, Veronesi G, Pelosi G, de Pas T, Catalano G, de Braud F: Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. Ann Thorac Surg; 2005 Jan;79(1):234-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer.
  • BACKGROUND: Extended pneumonectomy with partial resection of the left atrium for lung cancer is not frequently performed; therefore, its results remain controversial.
  • METHODS: From November 1996 to December 2003, 15 patients underwent extended pneumonectomy with partial resection of the left atrium for lung cancer, without cardiopulmonary bypass.
  • Nine patients (60%) underwent induction chemotherapy.
  • Pathologic analysis of the specimens identified 8 patients (53%) with N2 disease, 5 patients (33%) with N1 disease, and 2 patients with N0 disease.
  • The T status was T4 in 10 patients, pT3 in 3 patients, and T0 in the remaining 2 patients.
  • The were 10 squamous cell carcinomas (60%), 2 adenocarcinomas, 1 adenosquamous carcinoma, 1 mucoepidermoid carcinoma, and 1 atypical carcinoid tumor.
  • At completion of the study, 9 patients (60%) were still alive, with 8 showing no evidence of disease.
  • CONCLUSIONS: Extended pneumonectomy with partial resection of the left atrium for advanced lung cancer is a feasible procedure, with low postoperative morbidity and mortality.
  • In fact, it can lead to excellent local control of the disease, if not to a permanent cure in select patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Heart Atria / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Antineoplastic Agents / therapeutic use. Arrhythmias, Cardiac / epidemiology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Cardiopulmonary Bypass. Combined Modality Therapy. Databases, Factual. Female. Humans. Length of Stay / statistics & numerical data. Life Tables. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / epidemiology. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620949.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 11
  •  go-up   go-down


52. Kunnimalaiyaan M, Chen H: The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs; 2006 Feb;17(2):139-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?
  • Neuroendocrine (NE) tumors such as medullary thyroid cancer, carcinoid, small cell lung cancer and pheochromocytoma are metastatic in nature, and secrete biogenic amines and hormones.
  • In this review, we will discuss the possibility that activation of the Ras/Raf signaling pathway may be a therapeutic target for patients with select NE tumors.
  • In-vitro activation of Raf-1 in NE tumors either by expression of the ectopic catalytic domain of Raf-1 or by a pharmacologic drug, ZM336372, resulted in growth inhibition.
  • In addition, activation of the Ras/Raf pathway led to a significant reduction in NE markers such as serotonin, chromogranin A and calcitonin.
  • These data support development of Raf-1-activating compounds for treatment of patients with NE tumors of selective subtypes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neuroendocrine Tumors / drug therapy. Proto-Oncogene Proteins c-raf / metabolism. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428931.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK063015; United States / NIDDK NIH HHS / DK / DK064735; United States / NIDDK NIH HHS / DK / DK066169
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf
  • [Number-of-references] 42
  •  go-up   go-down


53. Yu DC, Grabowski MJ, Kozakewich HP, Perez-Atayde AR, Voss SD, Shamberger RC, Weldon CB: Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg; 2010 Jun;45(6):1090-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lung tumors in children and adolescents: a 90-year experience.
  • PURPOSE: Primary lung tumors in children are rare.
  • A wide range of histopathologic tumor types occurs.
  • This study aims to determine the incidence of different primary lung tumors in children and to contribute data leading to the development of evidence-based treatment models.
  • Patients were included if they had primary, nonhematologic lung tumors.
  • Simple squamous papillomas subjected to endoscopic biopsy and not resected, and vascular lesions associated with multisystem lesions, such as hereditary hemorrhagic telangiectasia, were excluded.
  • RESULTS: Forty patients were identified (23 boys, 17 girls) with a mean age of 9.6 years (range, 3 months to 19 years).
  • Fourteen distinct histopathologic tumor types were identified.
  • The most common tumor types were carcinoid (8), inflammatory myofibroblastic tumor (7), and pleuropulmonary blastoma (6).
  • Rare pediatric lung tumors including small cell carcinoma, adenocarcinoma, and pulmonary capillary hemangiomatosis were also seen.
  • Chemotherapy was used in 23% (9) and radiation in 20% (8) of the patients.
  • Of the 33 survivors, 28 had follow-up with a median duration of 29.5 months (mean, 63.2 months; range, 1-471 months).
  • CONCLUSIONS: Primary lung tumors in children are rare and histopathologically diverse.
  • The tumor spectrum involves many types not seen in adults, and unlike adults, patients rarely have a history of exposure to external predisposing factors.
  • Although complete resection remains the standard for treatment of most tumors, addition of adjuvant therapy is dependent on both tumor stage and histopathologic type.
  • [MeSH-major] Lung Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Male. Morbidity / trends. Prognosis. Retrospective Studies. Sex Distribution. Survival Rate / trends. Time Factors. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20620301.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Hogan BA, Thornton FJ, Brannigan M, Browne TJ, Pender S, O'Kelly P, Lyon SM, Lee MJ: Hepatic metastases from an unknown primary neoplasm (UPN): survival, prognostic indicators and value of extensive investigations. Clin Radiol; 2002 Dec;57(12):1073-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases from an unknown primary neoplasm (UPN): survival, prognostic indicators and value of extensive investigations.
  • AIM: The objectives of this study were to identify prognostic features for patients with hepatic metastases and unknown primary neoplasms (UPN), determine the common primary tumours, assess the value of diagnostic tests in finding these tumours, and evaluate the impact of therapy and knowledge of the primary tumour on patient survival.
  • Histopathology, diagnostic investigations and success at identifying the primary neoplasm were recorded.
  • In addition, in 70 patients with adenocarcinoma histology (M:F, 48:22; age range 27-91 years, median 65 years), treatment and survival data from the date of biopsy were recorded.
  • RESULTS: The histological spectrum included adenocarcinoma in 70, neuroendocrine in four, squamous cell carcinoma in four, small cell carcinoma in four, carcinoid in two, hepatoma in one and three others.
  • Extensive investigation identified a primary neoplasm in 16/88 patients (18%) including colorectal in six, gastric in two, lung in four, oesophageal in two, prostate in one and carcinoid in one.
  • Sixteen of 62 patients received active treatment with either surgery, chemotherapy, radiotherapy or a combination protocol.
  • The median survival for treated patients (49 days) versus untreated patients (52 days) was not significantly different (P=0.128).
  • Patients <65 years were more likely to receive active treatment than those >65 years (P=0.006).
  • Age with a hazard ratio (HR) of 1.01 (P=0.178), active treatment (HR=0.65;P=0.194), knowledge of the primary neoplasm (HR=0.60;P=0.213) and male gender (HR=0.88;P=0.642) had no significant effect on survival.
  • CONCLUSION: Although hepatic metastases are associated with poor prognosis, it is essential that a liver biopsy be performed to obtain a histological diagnosis.
  • Adenocarcinoma metastases carry a dismal prognosis, and no prognostic factors, including knowledge of the primary tumour, are significant for patient survival.
  • Extensive investigation is not warranted in patients with adenocarcinoma liver metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12475531.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Rothermel J, Wartmann M, Chen T, Hohneker J: EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol; 2003 Jun;30(3 Suppl 6):51-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EPO906 (epothilone B) is a potent member of a new class of microtubule-stabilizing cytotoxic agents known as epothilones.
  • In preclinical studies, EPO906 has shown anticancer activity both in vitro and in vivo against several cancer types, including models that are paclitaxel-resistant.
  • Importantly, in contrast to the taxanes, EPO906 retained activity against cancer cells either overexpressing the P-glycoprotein efflux pump or bearing tubulin mutations.
  • Tumor responses were seen in colorectal cancer as well as a variety of other tumor types, such as breast, ovarian, lung, and carcinoid in these two phase I trials.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Epothilones / pharmacology. Microtubules / drug effects
  • [MeSH-minor] Animals. Clinical Trials as Topic. Colorectal Neoplasms / drug therapy. Drug Screening Assays, Antitumor. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12802795.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epothilones; UEC0H0URSE / epothilone B
  • [Number-of-references] 22
  •  go-up   go-down


56. Langfort R, Rudziński P, Burakowska B: [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment]. Pneumonol Alergol Pol; 2010;78(1):33-46
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
  • Neuroendocrine tumors of the lung represent a broad spectrum of morphologic types that share specific morphologic, immunohistochemical, ultrastructural, and molecular characteristics.
  • The classification of neuroendocrine lung tumors has changed over the last decades and currently four categories are distinguished: typical carcinoid tumor, atypical carcinoid tumor, large cell neuroendocrine carcinoma and small cell carcinoma.
  • Neuroendocrine tumors of the lung comprise approximately 20% of all primary lung cancers.
  • Because of differences in clinical behavior, therapy, and prognosis, a reliable histological diagnosis, as well as clinical and pathological staging system are essential for an appropriate medical proceedings.
  • The most effective treatment of bronchial carcinoids and large cell neuroendocrine carcinoma in an early stage is complete surgical resection, whereas chemotherapy remains the primary treatment for small cell carcinoma.
  • All carcinoids are malignant tumors with the potential to metastasize.
  • The majority of patients with pulmonary carcinoid have an excellent survival, even if they present with lymph node metastases.
  • Large cell neuroendocrine and small cell carcinoma progress rapidly and are generally widespread at the moment of diagnosis.
  • Increased knowledge about pulmonary neuroendocrine tumors biology and the genetic characteristics, imply that carcinoid tumors appear to have a different etiology and pathogenesis than large cell neuroendocrine and small cell carcinoma.
  • In practice, it could be easiest to conceptualize this group of pulmonary tumors as a spectrum of malignancy ranging from the low grade typical carcinoid to the highly malignant large cell neuroendocrine and small cell carcinoma.
  • Typical carcinoid tumors associated with a fairly benign behavior should be classified as low-grade neuroendocrine tumor/carcinoma (G1) and atypical carcinoid tumors as intermediate-grade tumor/carcinoma (G2).
  • Whereas, large cell neuroendocrine and small cell carcinoma should be grouped together under the designation of high-grade neuroendocrine tumor/carcinoma (G3).
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / therapy. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Humans. Lung / pathology. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162517.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 67
  •  go-up   go-down


57. Masi G, Fornaro L, Cupini S, Loupakis F, Vasile E, Baldi GG, Stasi I, Salvatore L, Falcone A: Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine. Nat Rev Clin Oncol; 2009 Nov;6(11):670-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.
  • BACKGROUND: A 61-year-old patient with no relevant medical or family history presented with a 2 month history of refractory dry cough that led to the diagnosis of typical carcinoid tumor of the lung metastatic to the mediastinal lymph nodes and liver.
  • She initially received a long-acting somatostatin analog (octreotide) and chemotherapy with cisplatin and etoposide, which was ineffective.
  • INVESTIGATIONS: Physical examination, laboratory test, chromogranin A test, CT scan, (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scan, (18)F-FDG-PET scan, fine-needle and tissue core liver biopsies.
  • DIAGNOSIS: Pulmonary spindle-cell carcinoid tumor with metastases to mediastinal lymph nodes and liver.
  • MANAGEMENT: Systemic treatment with oral capecitabine (1,500 mg/m(2) daily from day 1 to day 21) and intravenous liposomal doxorubicin (10 mg/m(2) on days 1, 8 and 15), both repeated every 4 weeks, administered concomitantly with long-acting octreotide 30 mg every 3 weeks.
  • The patient achieved a significant and long-lasting response with the combination of capecitabine and liposomal doxorubicin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Neuroendocrine / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Capecitabine. Cisplatin / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Doxorubicin / administration & dosage. Etoposide / therapeutic use. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Lymphatic Metastasis / pathology. Middle Aged. Octreotide / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861994.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; RWM8CCW8GP / Octreotide; U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Ubieto MA, Abós MD, Tardin AL, Razola P, Prats E, García F, Polo E, Yubero A, Banzo J: [Treatment of bone metastatic pain with Sm153-EDTMP. Evaluation of the analgesic response and the existence of differences according to the primary tumor and the metastatic pattern]. Rev Esp Med Nucl; 2005 Sep-Oct;24(5):297-304
MedlinePlus Health Information. consumer health - Pain Relievers.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of bone metastatic pain with Sm153-EDTMP. Evaluation of the analgesic response and the existence of differences according to the primary tumor and the metastatic pattern].
  • [Transliterated title] Tratamiento del dolor óseo metastásico con Sm153-EDTMP. Valoración de la respuesta analgésica y de la existencia de diferencias según el tipo de tumor y el patrón metastásico.
  • AIMS: To evaluate the response to Sm153-EDTMP treatment in patients with metastatic bone pain and the existence of differences in the response according to the scintigraphic pattern (99mTc-MDP) and the primary tumor.
  • MATERIAL AND METHODS: We have evaluated the response to Sm153-EDTMP treatment in 32 patients (17 male and 15 female) who received 38 doses (1 mCi/kg).
  • The primary tumor was prostate cancer in 15 patients, breast in 13, lung in 2, intestinal carcinoid in one and unknown in one.
  • Two types of response were considered: a) effective and b) non-effective.
  • In SS pattern there were 6 effective responses (60%) and 4 non-effective (40%) and 2 effective (28.57%) and 5 non-effective (71.53%) in RM pattern.
  • These differences did not reach statistical significance (p > 0.05).
  • We did not find differences in the response between prostate cancer (12 effective and 6 non-effective) and breast cancer (10 effective and 6 non-effective) (p = 0.79968).
  • CONCLUSIONS: Sm153-EDTMP treatment is efficacious in patients with metastatic bone pain with effective response in 63.15% of the treatments.
  • The response percentage was lower in patients with RM pattern but the differences did not reach statistical significance.
  • [MeSH-major] Analgesia. Analgesics, Non-Narcotic / therapeutic use. Bone Neoplasms / secondary. Organometallic Compounds / therapeutic use. Organophosphorus Compounds / therapeutic use. Pain / drug therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194461.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate
  •  go-up   go-down


59. Carretta A, Ceresoli GL, Arrigoni G, Canneto B, Reni M, Cigala C, Zannini P: Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases. Lung Cancer; 2000 Sep;29(3):217-25
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases.
  • Neuroendocrine tumors of the lung (NTL) are a distinct subset of tumors with a wide range of histological patterns and clinical behavior.
  • Controversy still exists as to the ideal diagnostic and therapeutic approach to these neoplasms.
  • A series of 44 consecutive NTL patients operated on at our Institution was retrospectively reviewed in order to critically analyze the diagnostic and therapeutic management.
  • A preoperative diagnosis was obtained in 11 patients (25%).
  • Pathological diagnosis was typical carcinoid (TC) tumor in 36 cases, atypical carcinoid (AC) in three and large-cell neuroendocrine carcinoma (LCNEC) in five.
  • One patient had preoperative chemotherapy.
  • Median follow-up time was 40 months for TC and 51.5 months for AC/LCNEC.
  • Recurrence of disease was observed in three patients with TC and in two with AC/LCNEC.
  • Survival was not influenced by tumor size, while lymph node metastases were associated with a worse prognosis.
  • In conclusion, our study confirms findings in the literature showing that TC and AC/LCNEC are clinically different, and that a differential preoperative diagnosis and treatment is necessary.
  • Surgery, with anatomical resection and lymphoadenectomy, remains the treatment of choice in all these tumors.
  • Laser treatment should be considered only as a palliative procedure or as a complementary technique to surgery.
  • The role of adjuvant treatments in AC and LCNEC is uncertain and should be evaluated in larger trials.
  • The prognostic role of biological factors such as cytometry and genetic markers requires further investigation before any definitive conclusions can be drawn.
  • [MeSH-major] Lung Neoplasms / surgery. Neuroendocrine Tumors / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10996424.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Petrella F, Leo F, Veronesi G, Solli P, Borri A, Galetta D, Gasparri R, Lembo R, Radice D, Scanagatta P, Spaggiari L: "Salvage" surgery for primary mediastinal malignancies: is it worthwhile? J Thorac Oncol; 2008 Jan;3(1):53-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Indications and results of salvage surgery in mediastinal tumors are still unclear.
  • This study analyzes a single-center experience to assess its mortality, morbidity, and long-term results.
  • METHODS: Mediastinal salvage surgery (MSS) was defined as surgical resection of persistent or recurrent primary mediastinal tumors after previous local treatments with curative intent or exclusive chemotherapy in case of bulky tumors.
  • Overall and disease-specific long-term survival was calculated.
  • Eleven patients suffered from thymic tumors (eight thymomas, three thymic carcinoma) whereas 10 patients suffered from nonthymic tumors (one lung adenocarcinoma + thymoma, two mediastinal monophasic sinovial sarcoma, one mediastinal neuroendocrine tumor, one mediastinal teratoblastoma, one mediastinal disgerminoma, one Hodgkin's lymphoma, one mediastinal atypic carcinoid, two medullary thyroid carcinoma).
  • Median operation time was 215 minutes (range 140-720).
  • With a median follow-up of 30.6 months, overall 1-, 3-, and 5-year Kaplan-Meier survival was 89.7, 71.2, and 56.6%, respectively.
  • CONCLUSIONS: MSS can offer a chance of curative treatment in selected patients with an acceptable morbidity and mortality.
  • Thymic tumors obtain the best results in term of long-term survival.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Dysgerminoma / pathology. Dysgerminoma / surgery. Female. Follow-Up Studies. Hodgkin Disease / pathology. Hodgkin Disease / surgery. Humans. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Male. Middle Aged. Morbidity. Mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Retrospective Studies. Salvage Therapy / methods. Sarcoma / pathology. Sarcoma / surgery. Survival Analysis. Teratoma / pathology. Teratoma / surgery. Thymoma / pathology. Thymoma / surgery. Thymus Neoplasms / pathology. Thymus Neoplasms / surgery. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166841.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Hamaguchi T, Doi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, Fuse N, Ohtsu A, Matsumoto S, Takanashi M, Matsumura Y: Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res; 2010 Oct 15;16(20):5058-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.
  • EXPERIMENTAL DESIGN: Patients with solid tumors refractory to standard therapy, or for which no standard therapy is available, were enrolled.
  • NK012 was administered as a 30-minute infusion every 3 weeks.
  • No UGT1A1*28 homozygous patients were enrolled.
  • Nonhematologic toxicity, especially diarrhea, was mostly grade 1 or 2 during study treatments.
  • Two of nine patients had DLT during cycle 1 at the 28 mg/m(2) dose level.
  • DLTs were mostly neutropenia or a related event.
  • Polymer-bound SN-38 (NK012) and SN-38 released from NK012 were slowly eliminated from the plasma, with a terminal-phase half-life of approximately 140 and 210 hours, respectively.
  • A refractory esophageal cancer patient and a lung carcinoid tumor patient had an objective response and continued the study treatment for 5 and 12 months, respectively.
  • CONCLUSIONS: NK012 was well tolerated and showed antitumor activity including partial responses and several occurrences of prolonged stable disease across a variety of advanced refractory cancers.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Camptothecin / analogs & derivatives. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Nanoparticles / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20943763.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


62. Wang WP, Guo C, Berney DM, Ulbright TM, Hansel DE, Shen R, Ali T, Epstein JI: Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases. Am J Surg Pathol; 2010 Apr;34(4):519-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases.
  • Testicular carcinoid tumors are rare with only limited studies.
  • We identified 29 primary testicular carcinoid cases from 7 academic institutions.
  • The most common presenting symptom was the sole finding of either a testicular mass or swelling seen in 15/24 cases with available information.
  • The next most common mode of presentation was as an incidental finding seen in 6 cases.
  • Two patients had carcinoid syndrome including diarrhea, hot flashes, and palpitations.
  • Nineteen were pure carcinoid tumors, 3 were associated with cystic teratoma, 2 with cysts lacking epithelial lining, 4 with epidermoid cyst, and 1 with dermoid cyst.
  • All 29 primary carcinoids lacked associated intratubular germ cell neoplasia, unclassified type.
  • Mitotic figures were rare in primary carcinoid tumors with only 3 cases showing more than 2 per 10 HPF; necrosis was found in only 1 case.
  • Of the 28 cases found premortem, treatment included focal excision in 3 patients and radical orchiectomy in 25 patients.
  • Follow-up, available in 24 cases, ranged from 1 to 228 months (mean 52.7 mo); of the 20 patients with testicular typical carcinoid tumors found premortem, all were alive at last follow-up without recurrences or metastases.
  • Of the 4 patients with a primary atypical carcinoid tumor, 1 at the time of diagnosis had retroperitoneal and lung metastases who after chemotherapy underwent resection of the retroperitoneal tumor showing metastatic yolk sac tumor and embryonal carcinoma.
  • After resection, serum AFP levels remained elevated and the patient is scheduled for salvage chemotherapy and bone marrow transplant.
  • The other 2 patients with atypical carcinoid and follow-up had no evidence of disease at 68 and 114 months.
  • Most primary carcinoid tumors of the testis have a benign clinical course even if associated with epidermoid/dermoid cysts, or histologically mature teratoma.
  • However, lesions with the morphology of atypical carcinoid can occasionally exhibit metastatic spread.
  • [MeSH-major] Carcinoid Tumor / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2010 Jul;34(7):1075. Ubright, Thomas M [corrected to Ulbright, Thomas M]
  • (PMID = 20351489.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


63. Keto Y, Ebata M, Okabe S: Gastric mucosal changes induced by long term infection with Helicobacter pylori in Mongolian gerbils: effects of bacteria eradication. J Physiol Paris; 2001 Jan-Dec;95(1-6):429-36
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric mucosal changes induced by long term infection with Helicobacter pylori in Mongolian gerbils: effects of bacteria eradication.
  • Using Mongolian gerbils, this study examined whether or not eradication of the bacteria with drugs at specified times after infection prevents the development of mucosal changes.
  • Four or 8 months after H. pylori inoculation, eradication was performed by concurrent treatment with omeprazole+clarithromycin.
  • Immediately after treatment ended, in both the 5 and 9 month groups, it was verified that H. pylori was completely eradicated.
  • In addition, atrophic gastritis, intestinal metaplasia, carcinoids, and adenocarcinomas were histologically observed in the animals.
  • In animals eradicated after 4 months and autopsied after 18 months, however, such mucosal changes were not observed.
  • It was concluded that early eradication of H. pylori infection with drug therapy can prevent severe gastric mucosal changes, to include adenocarcinomas, in Mongolian gerbils.
  • [MeSH-minor] Animals. Anti-Bacterial Agents / therapeutic use. Anti-Ulcer Agents / therapeutic use. Body Weight. Chronic Disease. Clarithromycin / therapeutic use. Gerbillinae. Male. Omeprazole / therapeutic use. Proton Pump Inhibitors. Time Factors

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11595471.001).
  • [ISSN] 0928-4257
  • [Journal-full-title] Journal of physiology, Paris
  • [ISO-abbreviation] J. Physiol. Paris
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 0 / Proton Pump Inhibitors; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole
  •  go-up   go-down


64. Chen F, Sato T, Fujinaga T, Sakai H, Miyahara R, Bando T, Date H: Surgical management of bronchopulmonary typical carcinoid tumors: an institutional experience. Interact Cardiovasc Thorac Surg; 2010 Dec;11(6):737-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of bronchopulmonary typical carcinoid tumors: an institutional experience.
  • Bronchopulmonary typical carcinoid tumors are well known as low-grade malignant tumors with fairly benign behaviors; however, distant metastasis after complete resection and multiple carcinoid tumors in the resected lungs have been sporadically reported.
  • Lesser resections are preferred including lung-sparing surgery, while the importance of major surgical resections is also emphasized.
  • For better understanding of bronchopulmonary typical carcinoid tumors, we reviewed our institutional experience.
  • Eight patients with bronchopulmonary typical carcinoid tumors underwent complete pulmonary resection.
  • In one patient who received a lobectomy for a peripheral nodule, multiple carcinoid tumors were found in the resected specimen.
  • No patients received any adjuvant chemotherapy or radiotherapy after pulmonary resection.
  • In one patient, tumors recurred at the bronchial stump and in the liver approximately five years after complete pulmonary resection.
  • Despite a small number of cases, our study supported the idea that bronchopulmonary typical carcinoid tumors might require major surgical procedures and that complete pulmonary resection of typical carcinoid tumors could expect long-term survival.
  • [MeSH-major] Bronchial Neoplasms / surgery. Carcinoid Tumor / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Biopsy. Bronchoscopy. Female. Humans. Japan. Liver Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20852330.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Abdel Rahman AR: Bronchoplasty for primary broncho-pulmonary tumors. J Egypt Natl Canc Inst; 2010 Mar;22(1):73-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchoplasty for primary broncho-pulmonary tumors.
  • BACKGROUND: Parenchyma-sparing procedures are widely used in patients with low-grade malignancies of the airway when anatomically suited lesions exist.
  • This study was conducted to evaluate the short-term and the long-term results of bronchoplastic procedures for patients with centrally located primary bronchopulmonary tumors.
  • METHODS: Between 2000 and 2009, 36 patients with primary lung tumors required bronchoplasty were retrospectively analyzed.
  • Preoperative assessment included computed tomography (CT) of the chest, bronchoscopy, and spirometry.
  • Pre operative diagnosis was acheived by bronchoscopy for all patients, mediastinoscopy was done for patients with primary lung cancer.
  • Neo adjuvant chemotherapy was given for 6 patients with non small cell lung cancer (NSCLC).
  • Twelve patients (33.3%) suffered post-operative problems.
  • Post operative pathology revealed: 27 patients with typical carcinoid, 2 with atypical carcinoid, 4 with squamous cell carcinoma, 2 with adenocarcinoma and one with hamartoma.
  • Pathological TNM staging revealed: 17 patients with stage IA, 11 with IB, 5 with IIA and 2 with stage IIIA.
  • Two patients died with disseminated disease 1.5 year and 2 years after surgery.
  • The patient with hamartoma developed local recurrence 5 years later and re-excision was done.
  • One patient with lung cancer developed bone metastases and was alive with disease, while the remaining 30 patients were alive and disease free.
  • CONCLUSION: Bronchoplastic resections achieve local control and long-term survival comparable to the standard resections in patients with carcinoid tumor and NSCLC in anatomically suited lesions.
  • KEY WORDS: Bronchoplasty - Primary - Lung - Tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21503009.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


66. Isaka T, Maruno M, Suzuki T, Sato M, Yoshimine T: Skull metastases from atypical pulmonary carcinoid tumor in a 19-year-old man. Neurol Med Chir (Tokyo); 2006 Dec;46(12):609-13
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skull metastases from atypical pulmonary carcinoid tumor in a 19-year-old man.
  • A 19-year-old man presented with a rare skull metastasis from atypical pulmonary carcinoid tumor (APCT) manifesting as headache, diplopia, and cough.
  • Head magnetic resonance imaging showed a skull base tumor extending from the posterior clinoid process to the clivus, and calvarial tumors in the right temporal and occipital bones.
  • Chest and abdominal computed tomography showed a round tumor, 4 cm in diameter, in the lower lobe of the right lung and multiple small tumors in the liver.
  • Surgery for the calvarial tumor in the right temporal bone was performed on June 27, 2003.
  • The histological diagnosis was skull metastasis of neuroendocrine tumor.
  • Partial resection of the right lower lobe was performed for the lung tumor on August 22, 2003.
  • The histological diagnosis was atypical carcinoid tumor.
  • Subsequent adjuvant systematic chemotherapy was performed.
  • The patient died of progression of the tumors in the lung and liver on April 19, 2004.
  • We must consider APCT in the differential diagnosis of pulmonary tumors in adolescents, and perform follow-up observation or treatment, including surgery, if APCT is suspected.
  • [MeSH-major] Carcinoid Tumor / secondary. Lung Neoplasms / pathology. Skull Neoplasms / secondary

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185889.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


67. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol; 2001 Sep;12(9):1295-300
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients.
  • BACKGROUND: Carcinoid tumours are rare malignant neuroendocrine tumours.
  • In 1992 octreotide was introduced in the Netherlands as a palliative treatment for the carcinoid syndrome in metastatic carcinoid disease.
  • The aims of this epidemiological study were to evaluate epidemiological data and the impact of octreotide on survival in metastatic carcinoid disease.
  • PATIENTS AND METHODS: Between 1989 and 1996, 2391 patients with carcinoid disease were diagnosed in the Netherlands.
  • Under the age of 35 years, appendiceal carcinoid was the most frequently diagnosed primary site.
  • Incidence of distant metastases at diagnosis for appendix and lung primary sites was 1.6% and 5.5%, compared to 40%, in the other primary sites.
  • In metastatic disease, however, only year of diagnosis after 1992 independently predicted survival (P = 0.012).
  • Improved survival in metastatic carcinoid disease might relate to the use of octreotide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697843.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


68. Basaria S, McCarthy EF, Belzberg AJ, Ball DW: Case of an ivory vertebra. J Endocrinol Invest; 2000 Sep;23(8):533-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of an osteoblastic vertebral lesion (ivory vertebra) includes metastatic prostate cancer, lung cancer, lymphoma, osteosarcoma and Paget's disease.
  • We report a case of a man who was initially diagnosed with Paget's disease on vertebral biopsy.
  • He failed to respond to conventional bisphosphate therapy.
  • The review of the original biopsy specimen showed metastatic carcinoid tumor involving the bone marrow.
  • The various features of carcinoid tumors metastasizing to the skeleton are briefly reviewed.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Liver Neoplasms / diagnosis. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Alendronate / therapeutic use. Alkaline Phosphatase / blood. Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Diphosphonates / therapeutic use. Humans. Lumbar Vertebrae. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Osteitis Deformans / drug therapy. Osteoblasts / pathology. Technetium. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Alendronic acid .
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1973 May;107(2):327-30 [4695897.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2B):1243-9 [9615795.001]
  • [Cites] Thorax. 1977 Aug;32(4):509-11 [929495.001]
  • [Cites] Clin Exp Rheumatol. 1994 Mar-Apr;12(2):228-9 [8039297.001]
  • [Cites] Skeletal Radiol. 1991;20(2):149-51 [2020865.001]
  • [Cites] Clin Biochem. 1987 Aug;20(4):225-30 [3319285.001]
  • (PMID = 11021770.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Diphosphonates; 7440-26-8 / Technetium; EC 3.1.3.1 / Alkaline Phosphatase; OYY3447OMC / pamidronate; X1J18R4W8P / Alendronate
  •  go-up   go-down


69. Francia G, Davì MV, Montresor E, Colato C, Ferdeghini M, Lo Cascio V: Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine? J Endocrinol Invest; 2006 Apr;29(4):358-62
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine?
  • Although inferior petrosal sinus sampling did not show any significant difference between central and peripheral ACTH concentration, suggesting an ectopic source of ACTH secretion, diagnostic imaging was negative and Cushing's disease due to hyperplasia of the pituitary intermediate lobe was suspected.
  • Medical treatment with bromocriptine and cyproheptadine led to a rapid and stabile normalization of adrenal function, so that after two months cyproheptadine was stopped and bromocriptine was tapered to a smaller dose.
  • An attempt to discontinue medical treatment, carried out 3 yr later, was followed by a quick increase of ACTH and cortisol levels, which were normalized by the resumption of the bromocriptine.
  • Adrenal function remained normal until 1994 when hypercortisolism relapsed despite the treatment.
  • Chest radiography and computed tomography (CT) scan detected a 6 mm nodule in the middle lobe of the lung which proved to be a neuroendocrine tumor, with immunohistochemical positivity for ACTH.
  • Nests of neuroendocrine cells (tumorlets) were also demonstrated in the surrounding lung tissue.
  • Although cyclical spontaneous Cushing's syndrome could not be excluded, there was strong evidence that medical treatment with bromocriptine might have played a key role in long-lasting remission.
  • To our knowledge, this is the second case described in literature of Cushing's syndrome caused by neuroendocrine lung tumor responsive to bromocriptine.
  • [MeSH-major] ACTH Syndrome, Ectopic / complications. ACTH Syndrome, Ectopic / drug therapy. Bromocriptine / therapeutic use. Carcinoid Tumor / complications. Carcinoid Tumor / drug therapy. Cushing Syndrome / etiology. Lung Neoplasms / complications. Neoplasm Regression, Spontaneous


70. Nogales FF, Buriticá C, Regauer S, González T: Mucinous carcinoid as an unusual manifestation of endodermal differentiation in ovarian yolk sac tumors. Am J Surg Pathol; 2005 Sep;29(9):1247-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoid as an unusual manifestation of endodermal differentiation in ovarian yolk sac tumors.
  • We present, for the first time, two yolk sac tumors (YST) in women 37 and 18 years of age, one with a typical parietovisceral pattern and the other with a glandular pattern, which were associated with extensive areas of mucinous carcinoid (MC).
  • The tumor in the first case had numerous nodules of tubulopapillary YST that merged with well-differentiated MC.
  • This patient responded well to chemotherapy.
  • The tumor in the second case consisted of an AFP-positive glandular YST, with a glandulopapillary pattern closely resembling fetal lung type adenocarcinoma, coexisting with an AFP-negative, cytokeratin 20-positive, atypical MC; transitional areas between the two components were also seen.
  • AFP levels became negative during the course of disease paralleling the disappearance of the YST component and the overgrowth of an increasingly anaplastic MC.
  • The patient died 1 year after diagnosis.
  • It is important to differentiate the yolk sac and carcinoid components due to their different responses to chemotherapy and to evaluate the possibility of mucinous carcinoid developing into a highly aggressive carcinoma.
  • [MeSH-major] Carcinoid Tumor / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Immunohistochemistry. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096416.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  •  go-up   go-down


71. Klee H, Vestring T, Bittmann I: [Pleural metastases of a typical bronchial carcinoid 7 years after lobectomy]. Pneumologie; 2008 Oct;62(10):607-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural metastases of a typical bronchial carcinoid 7 years after lobectomy].
  • BACKGROUND: Bronchial carcinoids are a rare differential diagnosis of solitary pulmonary nodes.
  • Because of their typical manifestation in the major bronchi, carcinoid tumours are visible regularly via bronchoscopy where they show a typical picture.
  • In lymph node-negative disease a favourable outcome can be expected.
  • Typically metastases develop in the lung, liver, brain, bone and adrenal glands.
  • CASE REPORT: Seven years after lobectomy of a bronchial carcinoid, a slow-growing thickening of the pleura parietalis was noted in a 54-year-old male patient.
  • The histological diagnosis of pleural metastases was established via trans-thoracic punctation.
  • Pleural metastases of bronchial carcinoids are extremely rare.
  • Palliative cytotoxic chemotherapy was started.
  • CONCLUSIONS: The postoperative prognosis of bronchial carcinoids in lymph node-negative disease is excellent.
  • Metastatic disease--as in the rare case of pleural metastases shown here--remains a therapeutic dilemma.
  • Extensively evaluated concepts for adjuvant or palliative settings do not exist.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / surgery. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphatic Metastasis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711695.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Hatta R, Nambu Y, Suzuki S, Tachi Y, Oikawa T, Nakagawa K, Tuchihara K, Tobe T, Osanai K, Toga H, Takahashi K, Ohya N: [A case of atypical pulmonary carcinoid accompanying skin metastasis]. Nihon Kokyuki Gakkai Zasshi; 2004 Apr;42(4):357-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of atypical pulmonary carcinoid accompanying skin metastasis].
  • A 73-year-old woman underwent cranial surgery in 1999 after receiving a diagnosis of suspected malignant meningioma.
  • She began complaining of headache 2 years postoperatively, and around the same time, she noticed a painful skin tumor.
  • The skin tumor was diagnosed by skin biopsy as an atypical metastatic carcinoid tumor.
  • Systemic examination demonstrated a primary lesion in the left lung.
  • Pulmonary, skin and bone biopsy samples exhibited the same pathological findings as those of the atypical pulmonary carcinoid tumor.
  • She did not show any carcinoid symptoms.
  • EP therapy (etoposide + carboplatin) and CAV therapy (cyclophosphamide + doxorubicin + vincristin) were administered, but there was no clinical response.
  • The patient is currently doing well without chemotherapy and is being followed by the Outpatient Department.
  • [MeSH-major] Carcinoid Tumor / pathology. Carcinoid Tumor / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114855.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


73. Pitt SC, Chen H, Kunnimalaiyaan M: Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg; 2009 Jul;209(1):82-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.
  • BACKGROUND: In several types of cancer, upregulation of phosphatidylinositol 3-kinase (PI3K)-Akt signaling facilitates tumor cell growth and inhibits apoptosis.
  • Previous reports demonstrated that this pathway promotes growth, survival, and chemotherapy resistance in non-small cell and small cell lung cancer cells.
  • But the importance of PI3K-Akt signaling has not been explored in pulmonary carcinoids.
  • In this study, our objective was to establish the role of the PI3K-Akt signal transduction pathway in pulmonary carcinoid cells.
  • STUDY DESIGN: Human pulmonary carcinoid NCI-H727 cells were treated with LY294002 (0 to 100 microM), a well-known PI3K inhibitor, or transfected with Akt1 small interfering RNA (75 nM).
  • RESULTS: Treatment of NCI-H727 cells with LY294002 significantly reduced tumor cell growth (85.3%).
  • Similarly, Akt1 small interfering RNA transfection led to diminished tumor cell proliferation (31.3%).
  • Expression of Akt1 was reduced at all time points by transient Akt1 small interfering RNA transfection.
  • CONCLUSIONS: The PI3K-Akt pathway plays a role in both tumor cell growth and neuroendocrine hormone secretion in human pulmonary carcinoid cells.
  • Inhibition of Akt1, PI3K-Akt signaling, or a downstream mediator of this pathway may provide therapeutic approaches for patients with pulmonary carcinoid tumors.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Oncogene. 2008 Sep 18;27(42):5648-50 [18504432.001]
  • [Cites] Mol Cancer Ther. 2002 Sep;1(11):913-22 [12481412.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G245-54 [12851216.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):257-62 [14585353.001]
  • [Cites] Clin Cancer Res. 1997 Jul;3(7):1149-56 [9815794.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):910-7 [15956248.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):308-17 [16209885.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4134-9 [16537497.001]
  • [Cites] Oral Oncol. 2006 Apr;42(4):430-9 [16442835.001]
  • [Cites] Surgery. 2006 Dec;140(6):1009-14; discussion 1014-5 [17188151.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):3571-83 [17148458.001]
  • [Cites] Oncologist. 2007 Aug;12(8):942-51 [17766653.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2380-4 [18224693.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Jul 1;178(1):60-73 [18310482.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):5-21 [18473355.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):1772-81 [18644989.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1255-69 [19091780.001]
  • [Cites] Cell Signal. 2002 May;14(5):381-95 [11882383.001]
  • (PMID = 19651067.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009614-22; United States / NCI NIH HHS / CA / CA117117-01A2; United States / NCI NIH HHS / CA / CA109053-03; United States / NCI NIH HHS / CA / R21 CA117117-02; None / None / / T32 CA009614-19; United States / NCI NIH HHS / CA / CA109053-04; United States / NCI NIH HHS / CA / CA109053-05; None / None / / T32 CA009614-21; United States / NCI NIH HHS / CA / R01 CA109053-03; United States / NCI NIH HHS / CA / R01 CA109053-01A2; United States / NCI NIH HHS / CA / T32 CA009614-19; United States / NCI NIH HHS / CA / R01 CA109053; United States / NCI NIH HHS / CA / CA117117-02; United States / NCI NIH HHS / CA / R21 CA117117-01A2; United States / NCI NIH HHS / CA / R01 CA109053-04; None / None / / T32 CA009614-22; United States / NCI NIH HHS / CA / T32 CA009614-20; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / CA109053-01A2; United States / NCI NIH HHS / CA / CA109053-02; None / None / / T32 CA009614-20; United States / NCI NIH HHS / CA / R01 CA109053-05; United States / NCI NIH HHS / CA / R21 CA117117; United States / NCI NIH HHS / CA / R01 CA109053-02; United States / NCI NIH HHS / CA / T32 CA009614-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Morpholines; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS220145; NLM/ PMC2910111
  •  go-up   go-down


74. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP, Colby TV, Sheppard M, Shimosato Y, Koss MN, Falk R, Travis WD: Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol; 2000 Oct;31(10):1255-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary atypical carcinoid: predictors of survival in 106 cases.
  • Pulmonary neuroendocrine tumors (NE) include a spectrum of tumors from typical carcinoid (TC) to atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell carcinoma (SCLC).
  • Survival analysis was performed on 106 ACs with clinical follow-up from the AFIP and the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC).
  • The tumors fulfilled the 1999 WHO/IASLC criteria for AC of a NE tumor with a mitotic rate of 2 to 10 per 2 mm(2) of viable tumor or coagulative necrosis.
  • Of the clinical features, higher stage (P = .003) and a tumor size of 3.5 cm or greater (P = .003) were associated with a worse prognosis.
  • Multivariate analysis stratified for stage showed mitoses (P<.001), a tumor size of 3.5 cm or greater (P =.017), and female gender (P =.012) to be the only negative independent predictors of prognosis and the presence of rosettes (P = .016) to be the only independent positive predictor.
  • Within the category of AC, the patients with a higher mitotic rate had a significantly worse survival than those with a lower mitotic rate (P<.001) stratified for stage.
  • Chemotherapy or radiation therapy was given in 12 of 52 and 14 of 52 cases, respectively, but the data were insufficient to evaluate tumor response.
  • We conclude that AC is an aggressive neuroendocrine neoplasm with survival intermediate between TC and LCNEC and SCLC.
  • Higher mitotic rate, tumor size of 3.5 cm or greater, female gender, and presence of rosettes are the only independent predictors of survival.
  • Surgical resection remains the treatment of choice, and the role of chemotherapy and radiation therapy remains to be proven.
  • [MeSH-major] Carcinoid Tumor / mortality. Lung Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11070119.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


75. Lim E, Yap YK, De Stavola BL, Nicholson AG, Goldstraw P: The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors. J Thorac Cardiovasc Surg; 2005 Oct;130(4):969-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors.
  • OBJECTIVE: In pulmonary neuroendocrine tumors the realization that the extent of nodal disease is related to cell type has led to a controversy as to which is the dominant prognostic factor, stage or morphology.
  • METHODS: This is a historical cohort study of patients with confirmed pulmonary neuroendocrine tumors who underwent lung resection from 1980 through 2003.
  • The cell types for the 177 eligible patients were typical carcinoid in 89 (50%), atypical carcinoid in 15 (8%), large cell in 22 (13%), and small cell in 51 (29%).
  • The median time to follow-up was 7 years (first to third quartile, 2-12 years), and overall 5- and 10-year survivals were 86% (79%-90%) and 81% (74%-87%), respectively.
  • The univariable predictors of survival were age (P = .001), nodal stage (P = .01), and cell type (P < .001).
  • In the final multivariable model only age (P = .04) and cell type (P < .001) remained as independent predictors.
  • The hazard of death among patients with large cell or small cell lung cancer was highest in the first year and a half after diagnosis, reducing drastically thereafter.
  • CONCLUSIONS: In pulmonary neuroendocrine tumors cell type is the predominant determinant of survival.
  • The survival of patients with each cell type is sufficiently diverse to warrant different management strategies.
  • Conservative resection is feasible for typical carcinoids, but the effects of adjuvant chemotherapy need to be evaluated for the other subgroups.
  • [MeSH-major] Lung Neoplasms / mortality. Lung Neoplasms / pathology. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology
  • [MeSH-minor] Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16214506.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Fauroux B, Aynie V, Larroquet M, Boccon-Gibod L, Ducou le Pointe H, Tamalet A, Clément A: Carcinoid and mucoepidermoid bronchial tumours in children. Eur J Pediatr; 2005 Dec;164(12):748-52
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid and mucoepidermoid bronchial tumours in children.
  • The aim of the study was to determine the characteristic features and outcome of carcinoid or mucoepidermoid tumours in children.
  • A retrospective analysis of all patients treated for a carcinoid or mucoepidermoid tumour in France between 1984 and 2001 was performed.
  • There were 11 cases of carcinoid tumour and 6 cases of mucoepidermoid tumour.
  • The mean age of the patients was 10.5+/-3.0 years, with a range of 5 to 15 years.
  • Fibre optic bronchoscopy confirmed the presence of a bronchial tumour in all cases and endobronchial biopsies were diagnostic in 11 of 12 cases.
  • A chest CT scan revealed the presence of a hypervascular tumour in 8 of 12 patients.
  • The distribution of the location of the tumours was equal between the right and the left lung, and, in 9 cases, the airways were totally occluded by the tumour.
  • Complete surgical resection (lobectomy in 15 patients and pneumonectomy in 2 patients) was performed in all cases without pre-operative chemotherapy or radiotherapy.
  • In 2 patients, auscultation assymetry and an episode of haemoptysis revealed the recurrence of a mucoepidermoid tumour, successfully cured by removal of the tumour and chemotherapy and radiotherapy in one child.
  • CONCLUSION: Pulmonary carcinoid and mucoepidermoid tumours are rare in children.
  • Bronchoscopic removal should not be performed.
  • With aggressive surgical therapy, the prognosis is excellent.
  • A biopsy is needed for diagnosis and complete surgical removal is the treatment of choice.
  • Long-term results are excellent but a clinical follow-up is recommended.
  • [MeSH-major] Bronchial Neoplasms. Carcinoid Tumor. Carcinoma, Mucoepidermoid
  • [MeSH-minor] Adolescent. Child. Female. France. Humans. Male. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiol Med. 2002 Oct;104(4):273-84 [12569308.001]
  • [Cites] J Pediatr Surg. 1997 Jan;32(1):106-9 [9021584.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Aug;18(2):156-61 [10925223.001]
  • [Cites] Eur J Pediatr. 1986 Apr;145(1-2):130-2 [3732316.001]
  • [Cites] Cancer. 1979 Jul;44(1):315-22 [455258.001]
  • [Cites] Chest. 2001 Jun;119(6):1647-51 [11399686.001]
  • [Cites] Pediatr Radiol. 2001 May;31(5):348-50 [11373923.001]
  • [Cites] Prog Pediatr Surg. 1987;21:136-44 [3033744.001]
  • [Cites] Ann Thorac Surg. 1998 Sep;66(3):928-9 [9768954.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1133-6 [8308677.001]
  • [Cites] J Pediatr Surg. 1998 Oct;33(10):1561-2 [9802815.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):802-11 [7055788.001]
  • [Cites] Pediatr Surg Int. 1998 Sep;13(7):524-5 [9716686.001]
  • [Cites] Eur J Radiol. 1998 Nov;29(1):11-20 [9934553.001]
  • [Cites] Radiographics. 2002 Mar-Apr;22(2):351-65 [11896225.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2001 Jan;110(1):63-9 [11201811.001]
  • [Cites] Pediatr Pulmonol. 2003 Apr;35(4):318-22 [12629632.001]
  • [Cites] J Pediatr Surg. 2003 May;38(5):733-6 [12720182.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] Pediatr Radiol. 1992;22(8):563-7 [1337202.001]
  • [Cites] J Thorac Cardiovasc Surg. 1980 Apr;79(4):532-6 [7359932.001]
  • [Cites] Pediatr Hematol Oncol. 2002 Sep;19(6):421-8 [12186365.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):147-61 [9210721.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Jul-Aug;17(5):401-8 [10914051.001]
  • [Cites] Ann Thorac Surg. 1983 Jul;36(1):108-19 [6344822.001]
  • [Cites] Morphol Embryol (Bucur). 1980 Oct-Dec;26(4):335-40 [6450884.001]
  • [Cites] Eur Respir J. 1997 Aug;10(8):1761-6 [9272916.001]
  • [Cites] Pneumologie. 2003 May;57(5):272-7 [12784180.001]
  • (PMID = 16133240.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


77. Ratnagiri R, Singh SS, Majhi U, Kathiresan, Sateeshan: Large-cell neuroendocrine carcinoma of the kidney: Clinicopathologic features. Indian J Urol; 2009 Apr;25(2):274-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine tumors are rare entities which can arise in various sites of the body.
  • The presence of both neural and endocrine elements in conjunction characterises these tumors pathologically.
  • Most of these tumors are non secretory in nature, and arise in organs where there may not be any neuroendocrine elements.
  • Carcinoid tumors are the most common entities reported in the kidney.
  • There have been only a couple of case series of non-carcinoid neuroendocrine tumors of the kidney reported in literature.
  • Surgical resection appears to be the best available treatment modality.
  • Chemotherapy has been attempted with dismal results.
  • The biological behaviour is determined by the occurrence of metastases to the liver or lung.
  • We report a patient with a large cell neuroendocrine carcinoma of the kidney, who underwent radical resection and is doing well on follow-up.
  • The diagnosis was confirmed by immune-histochemistry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2007 Nov;100(5):1030-5 [17784891.001]
  • [Cites] Ann Pathol. 2000 Sep;20(4):357-60 [11015655.001]
  • [Cites] Scand J Urol Nephrol. 1996 Aug;30(4):325-7 [8908658.001]
  • [Cites] Curr Opin Oncol. 2005 Jul;17(4):386-91 [15933475.001]
  • (PMID = 19672368.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2710086
  • [Keywords] NOTNLM ; Immuno histochemistry / kidney / neuroendocrine tumors
  •  go-up   go-down


78. Kidd M, Schally AV, Pfragner R, Malfertheiner MV, Modlin IM: Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer; 2008 Mar 15;112(6):1404-14
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Currently, no consistently effective therapy is available to inhibit cell proliferation or metastasis of neuroendocrine tumor (NET) disease.
  • The effects of 4 novel peptides were analyzed: a targeted cytotoxic analog of luteinizing hormone-releasing hormone (LH-RH) analog (AN-152), a targeted cytotoxic analog of somatostatin (AN-238), and 2 antagonists of growth hormone-releasing hormone (GH-RH) on 3 NET (carcinoid) cell lines that expressed respective peptide receptors.
  • RESULTS: Proliferation of the LH-RH receptor-expressing lung NET, NCI-H720 line, was inhibited 2-fold by AN-152 containing doxorubicin compared with the chemotherapy alone (IC50 of 9.1 nM vs 24 nM).
  • This was associated with a reduction in Ki67 transcript and an increase in both caspase 3 mRNA levels and activity.
  • Proliferation of the GH-RH receptor expressing lung NET, NCI-H727 line, was inhibited by both GH-RH antagonists, the effects being mediated through changes in Ki67 expression, but not in caspase 3-mediated apoptosis.
  • The small intestinal NET, KRJ-I line, was 8x more sensitive to inhibition by AN-238 than to 2-pyrolino-doxorubicin, reflected by increased caspase 3 transcript as well as activity.
  • CONCLUSIONS: The data demonstrate GH-RH antagonists or peptide-linked antineoplastic agents such as AN-152 and AN-238 are effective inhibitors of NET proliferation in vitro.
  • Because peptide receptors such as those for GH-RH, LH-RH, and SST subtypes are commonly expressed by NETs, the development of antineoplastic agents targeted to specific tumor receptors may provide a more efficacious strategy than systemic chemotherapeutic agents currently in use.
  • [MeSH-major] Bronchial Neoplasms / drug therapy. Carcinoid Tumor / drug therapy. Cell Proliferation / drug effects. Growth Hormone-Releasing Hormone / antagonists & inhibitors. Intestinal Neoplasms / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Caspase 3 / metabolism. Cell Cycle / drug effects. Cytotoxins / pharmacology. Doxorubicin / analogs & derivatives. Doxorubicin / pharmacology. Flow Cytometry. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Gonadotropin-Releasing Hormone / pharmacology. Humans. Intestine, Small / drug effects. Intestine, Small / metabolism. Intestine, Small / pathology. Ki-67 Antigen / genetics. Ki-67 Antigen / metabolism. Pyrroles / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, LHRH / antagonists & inhibitors. Receptors, Somatostatin / antagonists & inhibitors. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18224665.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA1185285
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AN 238; 0 / Cytotoxins; 0 / Ki-67 Antigen; 0 / Pyrroles; 0 / RNA, Messenger; 0 / Receptors, LHRH; 0 / Receptors, Somatostatin; 27844X2J29 / LHRH, lysine(6)-doxorubicin; 33515-09-2 / Gonadotropin-Releasing Hormone; 80168379AG / Doxorubicin; 9034-39-3 / Growth Hormone-Releasing Hormone; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


79. Rougier P, Mitry E: Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion; 2000;62 Suppl 1:73-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in the treatment of neuroendocrine malignant tumors.
  • The efficacy of chemotherapy in digestive neuroendocrine tumors (NET) depends on primary site and histological differentiation.
  • Many reports have suggested a superior activity of chemotherapy for pancreatic NET than for metastatic carcinoid tumors with response rates ranging from 40 to 60% compared to 20%.
  • The standard chemotherapy for pancreatic NET is a combination of adriamycin and streptozocin and to a lesser extent a combination of 5FU and streptozocin.
  • In contrast, there is no clear standard chemotherapy for carcinoid tumors and if most oncologists use a combination of 5FU and streptozocin in the case of advanced, progressive and nonresectable carcinoid tumors, the results are mostly poor and the benefit seldom counterbalances its toxicity.
  • In these carcinoid tumors the combination of hepatic artery ischemia alternating with chemotherapy has given impressive results in one study, which, however, have never been confirmed.
  • Tumor cell differentiation is a major prognostic factor and some reports have suggested a higher chemosensitivity for undifferentiated or poorly differentiated NET with tumor response rates ranging from 41 to 69% when a VP16-CDDP combination is used.
  • This chemosensitivity is, unfortunately, as in small cell lung carcinomas, of short duration.
  • Related to this special problem and the number of other active treatments in NET, the place of chemotherapy always has to be discussed in a multidisciplinary fashion.
  • Surgical excision, chemoembolization, interferons and somatostatin analogues have to be emphasized and eventually combined with chemotherapy, especially in slowly growing tumors.
  • New active chemotherapy regimens have to be tested clearly in this orphan group of tumors which does not hold much interest to the pharmaceutical companies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10940691.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5W494URQ81 / Streptozocin; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 23
  •  go-up   go-down


80. Ducreux M, Baudin E, Schlumberger M: [Treatment strategy of neuroendocrine tumors]. Rev Prat; 2002 Feb 1;52(3):290-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment strategy of neuroendocrine tumors].
  • [Transliterated title] Stratégie de traitement des tumeurs neuro-endocrines.
  • Therapeutic strategy of neuroendocrine tumours is complex, due to their heterogeneity and to the fact that although generally slow growing, a significant proportion demonstrates aggressive tumour growth.
  • Symptomatic carcinoid syndrome and various pancreatic endocrine tumours with symptomatic syndromes are well controlled with somatostatin analogues.
  • Surgery remains the mainstay of treatment if the tumour can be resected.
  • Metastatic pancreatic neuroendocrine tumour are treated when resection is not feasible with combination chemotherapy using adriamycin and streptozotocin, which remains a standard of care.
  • In well differentiated tumour of the gut or the lung there is no clear standard of chemotherapy and treatment vary according to the tumour course.
  • In indolent cases, somatostatin analogues are the best treatment, in case of aggressive tumours chemoembolisation should be preferred when the disease is located or predominant in the liver.
  • Poorly differentiated tumours are treated by combination chemotherapy with etoposide and cisplatin, and surgery has no indication.
  • Gastrinoma and other pancreatic tumours arising in the context of multiple endocrine neoplasia type I disease need a specific therapeutic strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Growth Hormone / therapeutic use. Hormones / therapeutic use. Neuroendocrine Tumors / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Chemoembolization, Therapeutic. Doxorubicin / therapeutic use. Gastrinoma / drug therapy. Humans. Malignant Carcinoid Syndrome / drug therapy. Multiple Endocrine Neoplasia. Neoplasm Metastasis. Streptozocin / therapeutic use

  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11925720.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Hormones; 5W494URQ81 / Streptozocin; 80168379AG / Doxorubicin; 9002-72-6 / Growth Hormone
  • [Number-of-references] 23
  •  go-up   go-down


81. das Neves Pereira JC, da Silva AG, Soares F, Ab'Saber AM, Schmidt A, Rodrigues OR, Garippo A, Capelozzi M, de Campos JR, Takagaki T, Jatene FB, Martins S, Capelozzi VL: Nuclear and environment morphometric profile in tumor size and nodal metastasis of resected typical pulmonary carcinoid. Pathol Res Pract; 2004;200(6):459-67
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear and environment morphometric profile in tumor size and nodal metastasis of resected typical pulmonary carcinoid.
  • As the biologic behavior in lung tumors with neuroendocrine differentiation is highly dependent on cell death (apoptosis) and extracellular matrix invasion, Bcl2 and extracellular matrix density have been targeted as potentially useful tumor markers.
  • In this study, we sought to validate the importance of Bcl2 and ECM density and to study the relationships of Bcl2 and ECM density with clinical factors and other tumor or stromal markers.
  • We examined Bcl2 and several other markers in tumor tissues from 55 patients with surgically excised pulmonary typical carcinoid.
  • We used histochemistry, immunohistochemistry, and morphometry to evaluate the amount of tumor staining for Bcl2 and ECM; the surrogate markers for aggressive potential for our study were tumor size and lymph node metastasis determined at diagnosis.
  • Multivariate logistic model analysis demonstrated that after surgical excision control, tumor size was significantly related to nodal metastasis (P = 0.01), but quantitative staining of the tumor for Bcl2 and ECM added prognostic information and was as strongly prognostic as tumor size (P<0.01).
  • We concluded that tumor staining for Bcl2 and ECM in resected PTC is strongly related to tumor size and nodal metastasis.
  • Patients with > 3.1% and <9.8 microm2 staining in their tumors comprise a subset with a high hazard for nodal metastasis and may be an appropriate target for prospective studies of adjuvant chemotherapy after surgical resection.
  • [MeSH-major] Carcinoid Tumor / secondary. Cell Nucleus / pathology. Lung Neoplasms / pathology. Lymph Nodes / pathology. Thoracic Surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Child. Collagen / metabolism. Elastic Tissue / metabolism. Elastic Tissue / pathology. Extracellular Matrix / metabolism. Female. Humans. Ki-67 Antigen / metabolism. Lymphatic Metastasis / pathology. Male. Microcirculation. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15310149.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 9007-34-5 / Collagen
  •  go-up   go-down


82. Díaz ML, Villanueva A, Bastarrika G, Zudaire B, del Barrio LG, Noguera JJ: Non-electrocardiogram-gated multidetector-row computed tomography findings of cardiac pathology in oncologic patients. Curr Probl Diagn Radiol; 2009 Sep-Oct;38(5):206-17
MedlinePlus Health Information. consumer health - Heart Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-electrocardiogram-gated multidetector-row computed tomography findings of cardiac pathology in oncologic patients.
  • Multidetector-row computed tomography (MDCT) plays an essential role in oncologic imaging as the modality of mapping out the treatment strategy at staging, assessing response to the treatment, and following up patient outcome after the treatment.
  • In the group of oncologic patients, different tumoral and non-tumoral-related heart disorders can be found, for example, metastatic cardiac involvement (approximately 10% of patients with lung or breast cancer will develop metastases to the heart), paraneoplastic cardiac disorders, non-tumor-related heart disorders, and chemotherapy- and radiotherapy-related cardiac side effects.
  • MDCT plays a role in the detection of these entities.
  • We show the non-electrocardiogram-gated MDCT findings of oncology-related cardiac disorders to encourage radiologists to recognize and report cardiac findings in oncologic patients.
  • An adequate knowledge of the patient's medical history, previous treatments, and concomitant illnesses is essential to interpret heart findings in oncologic patients who undergo MDCT.
  • [MeSH-major] Heart Diseases / complications. Heart Diseases / radiography. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Neoplasms / pathology. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Carcinoid Heart Disease / radiography. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Male. Melanoma / radiography. Neoplasm Invasiveness. Neoplasm Staging. Pericardial Effusion / etiology. Pericardial Effusion / radiography. Pericardium. Prostatic Neoplasms / complications. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632498.001).
  • [ISSN] 1535-6302
  • [Journal-full-title] Current problems in diagnostic radiology
  • [ISO-abbreviation] Curr Probl Diagn Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


83. Zhao J, Wang MZ, Li LY, Zhang L, Zhong W: [Clinical features of pulmonary malignancies in patients younger than 30 years of age]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr;32(2):174-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of pulmonary malignancies in patients younger than 30 years of age].
  • OBJECTIVE: To analyse the clinical features of young patients with pulmonary malignancies.
  • METHOD: The clinical data of 58 young (< 30 years) patients with pulmonary malignancies who were treated in our hospital were retrospectively analyzed.
  • Accompanied tumors were seen in two patients.
  • Histories of smoking were noted in 10 patients (17.24%), and all of them were patients with epithelial tumor patients.
  • Four patients had family history of tumors.
  • The mean time from the onset of disease to confirmed diagnosis was (5.98+/-8.95) months.
  • The initial misdiagnosis rate was 37.9% (n=23), with pulmonary tuberculosis as the most common misdiagnosis.
  • The proportions of advanced-stage patients (stage III B and IV) and moderate to poor-differentiated tumor accounted for 59.26% (16/27) and 77.8% (14/18), respectively in 27 patients with non-small cell lung cancer.
  • The proportion of tumors in limited stage was 72.73% in 11 patients with small cell lung cancer, and most patients (54.55) were not sensitive to conventional chemotherapy.
  • In 6 patients with carcinoid, 4 patients were central and the other 2 patients were peripheral, and all of them presented as Cushing syndrome; CgA, AE1/AE3, Syn, and NSE were positive in immunohistochemical staining; and surgical operation was the main treatment for them.
  • In 6 patients with carcinomas of salivary gland type, all cases were central; no lymph nodes metastasis was found in the postoperative specimen; and surgical operation was also the main treatment for these patients.
  • In 3 patients with primitive neuroectodermal tumors, the tumors were highly malignant and invasive, and the development of primitive neuroectodermal tumors was closely related with pleura.
  • Immunohistochemical staining showed that the tumor cells were positive for CD99.
  • Multiple nodules in bilateral lungs were presented in 2 patients with anaplastic large cell lymphomas, in which CD30 was positive in tumor cells; chemotherapy was the main therapy for these two patients.
  • In one patient with synovial sarcoma, the tumor was giant and highly malignant and invasive; it was divided into many cavities filled with bloody fluid and white cheese-like substances; immunohistochemical analysis showed positive vimentin and AE1/AE3.
  • CONCLUSIONS: The pulmonary malignancies in young patients tend to be complicated.
  • The treatment strategy should be based on the specific conditions of each patient.
  • [MeSH-major] Lung Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450548.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


84. Sarjeant JM, Butany J, Cusimano RJ: Cancer of the heart: epidemiology and management of primary tumors and metastases. Am J Cardiovasc Drugs; 2003;3(6):407-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the heart: epidemiology and management of primary tumors and metastases.
  • Cardiac tumors, benign or malignant, are rare and most are benign.
  • The most common benign tumor is the cardiac myxoma.
  • Malignant cardiac tumors are usually sarcomas.
  • The pericardium can be the site of benign and malignant cardiac tumors, though metastatic tumors occur here far more commonly than do primary tumors.
  • Successful treatment for benign cardiac tumors is usually achieved by surgical resection.
  • Surgery for primary malignant tumors is, however, much less successful as complete resection is usually not possible.
  • Primary cardiac lymphoma may be successfully treated by chemotherapy.
  • Tumors that metastasize to the heart from other organs occur 100- to 1000-fold more commonly than primary cardiac tumors.
  • Metastatic spread to the heart has been identified in approximately one-fifth of all patients who have metastatic cancer with lung carcinoma being the most common primary tumor.
  • Treatment varies depending on the pathology of the primary tumor.
  • However, the aim of treatment is usually symptomatic relief.
  • With the advent of AIDS, Kaposi's sarcoma and high grade B cell lymphomas have also been identified in cardiac tissue.
  • The aim of this article is to review the epidemiology, clinical presentation, pathology and treatment of cardiac tumors.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Carcinoid Heart Disease / diagnosis. Carcinoid Heart Disease / pathology. Hematologic Neoplasms / diagnosis. Hematologic Neoplasms / pathology. Humans. Neoplasm Metastasis. Pericardium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14728061.001).
  • [ISSN] 1175-3277
  • [Journal-full-title] American journal of cardiovascular drugs : drugs, devices, and other interventions
  • [ISO-abbreviation] Am J Cardiovasc Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 62
  •  go-up   go-down


85. Santhanam S, Decatris M, O'Byrne K: Potential of interferon-alpha in solid tumours: part 2. BioDrugs; 2002;16(5):349-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of interferon-alpha in solid tumours: part 2.
  • The second part of this review examines the use of recombinant interferon-alpha (rIFNalpha) in the following solid tumours: superficial bladder cancer, Kaposi's sarcoma, head and neck cancer, gastrointestinal cancers, lung cancer, mesothelioma and ovarian, breast and cervical malignancies.
  • In superficial bladder cancer, intravesical rIFNalpha has a promising role as second-line therapy in patients resistant or intolerant to intravesical bacille Calmette-Guérin (BCG).
  • In HIV-associated Kaposi's sarcoma, rIFNalpha is active as monotherapy and in combination with antiretroviral agents, especially in patients with CD4 counts >200/mm(3), no prior opportunistic infections and nonvisceral disease. rIFNalpha has shown encouraging results when used in combination with retinoids in the chemoprevention of head and neck squamous cell cancers.
  • In neuroendocrine tumours, including carcinoid tumour, low-dosage (</=3 MU) or intermediate-dosage (5 to 10 MU) rIFNalpha is indicated as second-line treatment, either with octreotide or alone in patients resistant to somatostatin analogues.
  • Similarly, intraperitoneal IFNalpha may have a role in the treatment of minimal residual disease in ovarian cancer.
  • In breast cancer, the only possible role for IFNalpha appears to be intralesional administration for resistant disease.
  • IFNalpha may have a role as a radiosensitising agent for the treatment of cervical cancer; however, this requires confirmation in randomised trials.
  • On the basis of current evidence, the routine use of rIFNalpha is not recommended in the therapy of head and neck squamous cell cancers, upper gastrointestinal tract, colorectal and lung cancers, or mesothelioma.
  • Further data from randomised studies in solid tumours are needed where rIFNalpha has activity, such as neuroendocrine tumours, minimal residual disease in ovarian cancer, and cervical cancer.
  • Studies of IFNalpha-stimulated gene expression, which are now feasible, should help to identify molecular predictors of response and allow us to target therapy more selectively to patients with solid tumours responsive to IFNalpha.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12408739.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  • [Number-of-references] 391
  •  go-up   go-down


86. Capelli M, Bertino G, Morbini P, Villa C, Zorzi S, Benazzo M: Neuroendocrine carcinomas of the upper airways: a small case series with histopathological considerations. Tumori; 2007 Sep-Oct;93(5):499-503
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine carcinomas are rare tumors.
  • Diagnosis requires the recognition of the typical neuroendocrine architecture and morphology and the immunohistochemical confirmation of neuroendocrine differentiation.
  • In the 1991 WHO classification laryngeal neuroendocrine carcinomas have been divided into carcinoids, atypical carcinoids, small cell carcinomas and paragangliomas.
  • Atypical carcinoids in the head and neck region usually show an aggressive behavior analogous to poorly differentiated carcinomas, and are resistant to chemo- and radiotherapy.
  • For this reason, it was recently proposed to change their designation to "moderately differentiated neuroendocrine carcinomas".
  • We present the clinical and histopathological features of 2 moderately differentiated neuroendocrine carcinomas of the larynx, one large cell poorly differentiated neuroendocrine carcinoma of the oropharynx, and one small cell carcinoma of the minor salivary glands of the tongue.
  • The patient with small cell carcinoma was free from disease 26 months after radical surgery, while the other patients showed liver, lung and bone metastases 18, 26 and 24 months after the diagnosis despite radical surgery or concomitant intra-arterial chemotherapy and radiotherapy.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Lung Neoplasms / pathology. Neuroendocrine Tumors / pathology. Oropharyngeal Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Combined Modality Therapy. Humans. Immunoenzyme Techniques. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038886.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Lito P, Pantanowitz L, Marotti J, Aboulafia DM, Campbell V, Bower M, Dezube BJ: Gastroenteropancreatic neuroendocrine tumors in patients with HIV infection: a trans-Atlantic series. Am J Med Sci; 2009 Jan;337(1):1-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastroenteropancreatic neuroendocrine tumors in patients with HIV infection: a trans-Atlantic series.
  • BACKGROUND: Non-AIDS-defining cancers are an important problem in HIV-infected patients.
  • The occurrence of neuroendocrine (NE) tumors in sites other than the lung and skin has not been well characterized in the setting of concurrent HIV infection.
  • METHODS: HIV-positive patients with biopsy-confirmed NE tumors localized to the gastrointestinal tract were identified based on the personal archives of the authors.
  • A retrospective chart review was performed, and data regarding demographics, HIV status, presenting symptoms and signs, diagnostic work-up, therapeutic interventions, and outcome were extracted.
  • RESULTS: We identified 4 adult patients, mean age 42 years (range: 37-47) infected with HIV, who developed NE tumors originating in their gastrointestinal tact.
  • They had only moderate immunosuppression with a median CD4 count of 497 cells/mm (range: 182-1100) and chronic HIV infection (2-15 years duration).
  • A specialized diagnostic work-up was required, including serum chromogranin and urinary 5-hydroxyindoleacetic acid levels, colonoscopy, radioactive isotope scans, and the demonstration of NE differentiation in procured pathologic material.
  • The spectrum of tumors ranged from benign (typical carcinoid) to highly aggressive neoplasms (NE carcinoma).
  • Treatment with octreotide, surgical resection, or systemic chemotherapy provided effective symptomatic relief and was associated with a favorable outcome, despite metastases in 2 patients.
  • CONCLUSIONS: These cases serve to broaden the spectrum of neoplasms that may be encountered in the current HIV era, and illustrate the difficulty in establishing the diagnosis of NE tumors in the context of HIV infection.
  • [MeSH-major] Gastrointestinal Neoplasms / etiology. HIV Infections / complications. Neuroendocrine Tumors / etiology. Pancreatic Neoplasms / etiology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155751.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Dörffel Y, Wermke W: Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography. Ultraschall Med; 2008 Oct;29(5):506-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography.
  • PURPOSE: The aim of this study was to characterize the ultrasonographic features of neuroendocrine tumors (NET) and their metastases with contrast-enhanced ultrasonography (CEUS) and to compare this to clinical data.
  • MATERIALS AND METHODS: During a period of 5 years, 82 patients with 83 histologically proven NET were prospectively examined using conventional US and pulse inversion US with a second generation contrast agent (SonoVue, Contrast Pulse Sequencing) focusing on the arterial (10-20 s p. i.), capillary (20-25 sec p.i.
  • 69 patients had metastases in the abdominal tract, including eight patients with poorly differentiated neuroendocrine carcinomas with high-grade behavior.
  • In 31 patients the proliferation index (MIB-1) of the NET was < or = 2%, in 46 patients > 2%, in 6 patients > or = 20%.
  • RESULTS: In NET of the lung, stomach, and colon we found only hypoechoic or isoechoic liver metastases.
  • NET of the small intestine and pancreas represented hypoechoic, isoechoic, and/or hyperechoic liver lesions, sometimes combined.
  • Insulin producing tumors (6) had hypoechoic metastases.
  • Necrotic areas (25/83) were detected after interferon therapy, embolization, systemic chemotherapy, and radiofrequency ablation of liver metastases, but did not develop after somatostatin receptor radionuclide therapy.
  • In large NET (> 3 cm) with a proliferation index of > 2%, necrotic areas appeared spontaneously.
  • In 93% (77/83) of the cases the NET and their metastases showed an early arterial influx of microbubbles.
  • The hypervascularized tissue was found in the primary lesions, in liver, lymph node metastases and any kind of abdominal metastases.
  • In liver metastases with a proliferation index >2%, tumor arteries showed a chaotic growth pattern.
  • In 93% (77/83) the NET lesions appeared as dark "defects" at the beginning of the late phase.
  • CONCLUSION: CEUS with CPS demonstrates typical NET imaging characteristics.
  • In most cases real-time CEUS may replace other imaging techniques.
  • [MeSH-major] Contrast Media. Image Enhancement / methods. Neuroendocrine Tumors / ultrasonography
  • [MeSH-minor] Adult. Carcinoid Tumor / pathology. Carcinoid Tumor / ultrasonography. Humans. Jejunal Neoplasms / secondary. Jejunal Neoplasms / ultrasonography. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / ultrasonography. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography. Sensitivity and Specificity. Ultrasonography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241507.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


89. Reubi JC, Waser B: Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging; 2003 May;30(5):781-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.
  • Peptide receptors have been found to represent excellent targets for in vivo cancer diagnosis and therapy.
  • Recent in vitro studies have shown that many cancers can overexpress not only one but several peptide receptors concomitantly.
  • One of the challenges for nuclear medicine in this field in the coming decade will be to take advantage of the co-expression of peptide receptors for multireceptor tumour targeting.
  • In vitro receptor studies can reveal which peptide receptor is overexpressed in which tumour and which receptors are co-expressed in an individual tumour; such knowledge is a prerequisite for successful in vivo development.
  • One group of tumours of particular interest in this respect is the neuroendocrine tumours, which have previously been shown often to express peptide receptors.
  • This review summarises our investigations of the concomitant expression of 13 different peptide receptors, in more than 100 neuroendocrine tumours of the human intestine, pancreas and lung, using in vitro receptor autoradiography with subtype-selective ligands.
  • While the presence of VPAC(1) and sst(2) was detected in the majority of these neuroendocrine tumours, the other receptors, more differentially expressed, revealed a characteristic receptor pattern in several tumour types.
  • Ileal carcinoids expressed sst(2) and VPAC(1) receptors in virtually all cases and had CCK(1), CCK(2), sst(1) or sst(5) in approximately half of the cases; they were the only tumours of this series to express NMB receptors.
  • Most bronchial carcinoids had VPAC(1), while sst(1), sst(2) and CCK(2) were found in two-thirds of the cases and BB(3) in one-third of the cases.
  • These data provide evidence for the vast biological diversity of these neuroendocrine tumours.
  • Moreover, the results represent a basis for starting and/or optimising the in vivo targeting of these tumours by selecting the suitable radiopeptides for tumour diagnosis and/or therapy.
  • Finally, the data strongly encourage concomitant application of several radiopeptides to permit more efficient targeting of these tumours.
  • [MeSH-major] Drug Delivery Systems / methods. Neuroendocrine Tumors / metabolism. Receptors, Peptide / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Res Rev. 1995 Sep;15(5):389-417 [8531502.001]
  • [Cites] Eur J Nucl Med. 2000 Nov;27(11):1694-9 [11105826.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1841-6 [11752083.001]
  • [Cites] Am J Physiol. 1995 Nov;269(5 Pt 1):G628-46 [7491953.001]
  • [Cites] J Nucl Med. 2002 Jul;43(7):889-95 [12097458.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1848-55 [7958701.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Jul;29(7):855-62 [12111125.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1029-44 [10452322.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4636-41 [11389101.001]
  • [Cites] Lancet. 1998 Feb 7;351(9100):417-8 [9482300.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1922-31 [8620515.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1319-25 [11585290.001]
  • [Cites] Eur J Pharmacol. 2002 Dec 5;456(1-3):45-9 [12450568.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):26-34 [8644985.001]
  • [Cites] Eur J Pharmacol. 1998 Mar 12;345(1):103-10 [9593601.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1377-86 [9102227.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3105-12 [10850463.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):836-46 [11504080.001]
  • [Cites] Nucl Med Biol. 1996 Aug;23 (6):685-92 [8940711.001]
  • [Cites] Tumori. 2002 May-Jun;88(3):S25-8 [12365377.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2375-8 [9622077.001]
  • [Cites] Lancet. 1989 Feb 4;1(8632):242-4 [2563413.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] Experientia. 1987 Jul 15;43(7):750-61 [3036559.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1139-46 [11948125.001]
  • [Cites] Eur J Biochem. 2001 May;268(10):2828-37 [11358498.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):247-58 [12552343.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1152-9 [10070977.001]
  • [Cites] Pharmacol Rev. 1998 Jun;50(2):265-70 [9647867.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2806-14 [7673428.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1846-53 [7562054.001]
  • [Cites] Diagn Mol Pathol. 2000 Mar;9(1):47-57 [10718213.001]
  • (PMID = 12707737.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / GLP1R protein, human; 0 / Glucagon-Like Peptide-1 Receptor; 0 / Receptors, Bombesin; 0 / Receptors, Cholecystokinin; 0 / Receptors, Glucagon; 0 / Receptors, Peptide; 0 / Receptors, Somatostatin; 0 / Receptors, Vasoactive Intestinal Peptide
  • [Number-of-references] 37
  •  go-up   go-down


90. Béhé M, Behr TM: Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers; 2002;66(6):399-418
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
  • Nuclear medicine is engaged with the detection of pathological processes with the help of radionuclides.
  • An interesting approach is to target antigens, symporters, or receptors with diagnostic and therapeutic radionuclides.
  • Different peptide receptors like somatostatin, bombesin/GRP or VIP are (over)expressed on cancer cells, and are therefore an ideal target for the diagnosis and therapy in nuclear medicine with radiolabeled peptides.
  • The somatostatin analogue OctreoScan [octreotide coupled with diethylene-triamine-pentaacetate (DTPA)] can be labeled with In-111 and is widely used in nuclear oncology for the staging of different tumors (e.g., carcinoids).
  • The high sensitivity of the pentagastrin stimulation test in detecting primary or metastatic MTC indicates the presence of tumor, but its localization is often not possible.
  • This reaction of the tumor cells to the pentagastrin stimulation test suggests a widespread expression of the corresponding receptor type on human MTC.
  • Indeed, autoradiographic studies demonstrated cholecystokinin (CCK)-B/gastrin receptors not only in over 90% of MTCs, but in a high percentage of small cell lung cancers, stromal ovarian, and potentially a variety of other tumors, including gastrointestinal adenocarcinomas, neuroendocrine tumors, and malignant glioma.
  • The aim of our recent work was to develop and systematically optimize suitable radioligands for targeting CCK-B receptors in vivo and to investigate their role in the staging and therapy of MTC and other CCK-B receptor expressing malignancies.
  • They were members of the gastrin- or cholecystokinin families, or possessed characteristics of both, which differ by the intramolecular position of a tyrosyl moiety.
  • Their stability and affinity were studied and optimized in vitro and in vivo; their biodistribution and therapeutic efficacy were tested in preclinical models.
  • Best tumor uptake and tumor-to-nontumor ratios were obtained with members of the gastrin family, due to their superior selectivity and affinity for the CCK-B receptor subtype.
  • Radiometal-labeled derivatives of minigastrin showed excellent targeting of CCK-B receptor expressing tissues in animals and healthy human volunteers.
  • Preclinical therapy experiments in MTC-bearing animals showed significant antitumor efficacy.
  • In a subsequent clinical study, 75 MTC patients with metastatic MTC were investigated; 43 suffered of known, 32 of occult disease.
  • The normal organ uptake was essentially confined to the stomach (and to a lower extent, to the gallbladder and, in premenopausal women, to normal breast tissue) as a result of CCK-B receptor specific binding, and to the kidneys as excretory organs.
  • All tumor manifestations known from conventional imaging were visualized as early as 1 h p.i., with increasing tumor-to-background ratios over time; at least one lesion was detected in 29/32 patients with occult disease (patient-based sensitivity 91%).
  • Among them were local recurrences, lymph node, pulmonary, hepatic, splenic, and bone (marrow) metastases.
  • Eight patients with advanced metastatic disease were injected in a dose-escalation study with potentially therapeutic activities of a (90)Y-labeled minigastrin derivative at 4-6-weekly intervals (30-50 mCi/m(2) per injection for a maximum of four injections).
  • Two patients experienced partial remissions, 4 stabilization of their previously rapidly progressing disease.
  • These data suggest that CCK-B receptor ligands may be a useful new class of receptor binding peptides for diagnosis and therapy of a variety of (CCK-B receptor expressing) tumor types.
  • Initial therapeutic results are promising, but nephrotoxicity is a major concern to be solved.
  • [MeSH-major] Peptides / metabolism. Peptides / therapeutic use. Radiopharmaceuticals. Receptors, Cholecystokinin / metabolism. Thyroid Neoplasms / classification. Thyroid Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Thyroid cancer, medullary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc.
  • (PMID = 12658727.001).
  • [ISSN] 0006-3525
  • [Journal-full-title] Biopolymers
  • [ISO-abbreviation] Biopolymers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrins; 0 / Ligands; 0 / Peptides; 0 / Radiopharmaceuticals; 0 / Receptor, Cholecystokinin B; 0 / Receptors, Cholecystokinin; 0 / Receptors, Somatostatin; 60748-07-4 / minigastrin; 7A314HQM0I / Pentetic Acid
  •  go-up   go-down


91. Comaru-Schally AM, Schally AV: A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review). Int J Oncol; 2005 Feb;26(2):301-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review).
  • Carcinoid tumors were first described more than a century ago, but the treatment of patients with advanced disease remains a challenge to physicians.
  • The etiology of carcinoid tumors, the biologic determinants of the growth of these malignancies, as well as the high frequency of multiple carcinoid and/or non-carcinoid tumors in patients with this disease also remain to be elucidated.
  • A 5-decade analysis of 13,715 carcinoid tumors in the USA showed that distant metastases were demonstrated at the time of diagnosis in 12.9% of patients with this neoplasia.
  • The overall 5-year survival rate for all patients with carcinoids regardless of the site, was reported to be 67.2%.
  • The prognosis of patients with early stage disease is good and surgical resection is the standard form of treatment.
  • However, patients with metastatic dissemination have poor outcomes since chemotherapy is generally ineffective.
  • Radiation therapy may ease the pain of bone metastases.
  • The administration of long acting analogs of somatostatin can control the symptoms of diarrhea and flushing in patients with the malignant carcinoid syndrome.
  • However, a complete regression of metastatic carcinoid tumors following the administration of somatostatin analog octreotide has been reported so far in only 3 cases.
  • Other modalities of treatment, including liver transplantation and the administration of radiolabeled somatostatin analogs have likewise been applied in patients with advanced disease.
  • It is expected that advances in proteomics research will contribute to our understanding of the mechanisms of diseases and aid in designing new drugs.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoid Tumor / drug therapy. Carcinoid Tumor / mortality. Peptides / therapeutic use
  • [MeSH-minor] Female. Gamma Cameras. Gastrointestinal Neoplasms / drug therapy. Humans. Liver / pathology. Male. Neoplasm Metastasis. Prognosis. Proteomics. Somatostatin / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15645113.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides; 51110-01-1 / Somatostatin
  • [Number-of-references] 78
  •  go-up   go-down


92. Gustafsson BI, Hauso O, Drozdov I, Kidd M, Modlin IM: Carcinoid heart disease. Int J Cardiol; 2008 Oct 13;129(3):318-24
Genetic Alliance. consumer health - Heart Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid heart disease.
  • The carcinoid syndrome is usually evident when enterochromaffin (EC) cell-derived neuroendocrine tumors (carcinoids) metastasize to the liver.
  • In addition to carcinoid symptomatology, about 40% of patients exhibit carcinoid heart disease (CHD) with fibrotic endocardial plaques and associated heart valve dysfunction.
  • The mechanism behind CHD development is not fully understood, but serotonin (5-HT) is considered to be a major initiator of the fibrotic process.
  • Most patients present with right-sided heart valve dysfunction since pulmonary and tricuspid valves lesions are the most common (>95%) cardiac pathology.
  • Pathognomonic echocardiograpic features include immobility of valve leaflets and thickening and retraction of the cusps most commonly resulting in tricuspid valve regurgitation and pulmonary stenosis.
  • Therapeutic options include cardioactive pharmacotherapy for heart failure and, in selected individuals, cardiac valve replacement.
  • Previously valve replacement was reserved for advanced disease due to a perioperative mortality of >20% however in the last decade, technical advances as well as an earlier diagnosis have decreased surgical mortality to <10% and valve replacements are undertaken more frequently.
  • Although the improved prognosis might also reflect the increased use of surgical cytoreduction, hepatic metastatic ablative therapies and somatostatin analogs a robust correlation between diminution of circulating tumor products and an increased long-term survival in CHD has not been rigorously demonstrated.
  • [MeSH-major] Carcinoid Heart Disease / metabolism. Carcinoid Heart Disease / pathology
  • [MeSH-minor] Animals. Heart Valve Prosthesis Implantation / utilization. Heart Valves / pathology. Heart Valves / surgery. Humans. Serotonin / biosynthesis. Somatostatin / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18571250.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 333DO1RDJY / Serotonin; 51110-01-1 / Somatostatin
  • [Number-of-references] 65
  •  go-up   go-down


93. Modlin IM, Lye KD, Kidd M: Carcinoid tumors of the stomach. Surg Oncol; 2003 Aug;12(2):153-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid tumors of the stomach.
  • Interest in gastric carcinoid tumors has in recent time amplified considerably as the understanding of both their biological background and clinical significance has developed.
  • The increase in identification associated with the widespread availability of upper gastrointestinal endoscopy has facilitated diagnosis.
  • In addition concern related to the consequences of long-standing hypergastrinemia generated by the use of potent acid-suppressive medications has augmented both clinical and scientific focus on gastric neuro endocrine issues.
  • The elucidation of the regulatory mechanisms of the progenitor cell (ECL cell) of the gastric carcinoid tumor, the refinement of a pathological grading system for ECL cell proliferation, and the availability of specific immunohistologic identification techniques have further amplified the characterization of this lesion.
  • Although the putative malignant potential of gastric carcinoids may ultimately be of only modest concern in a background of hypergastrinemia its relationship to gastric adenocarcinoma is still enigmatic and worthy of further consideration.
  • This review will describe the molecular interrelationship between low-acid states, gastrin, and ECL cell proliferation and will discuss the pathological classification of the distinct types of gastric carcinoid tumors.
  • In addition, the clinical rationale of current diagnostic and therapeutic strategies will be examined, providing a logical basis for the formulation of appropriate management strategies for patient care.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Carcinoid Tumor / drug therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / physiopathology. Adenocarcinoma / secondary. Chronic Disease. Endoscopy. Enterochromaffin-like Cells / metabolism. Gastritis, Atrophic / physiopathology. Humans. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12946486.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 110
  •  go-up   go-down


94. Talton CC, Hopkins JO, Walley BD, Kincaid EH: Metastatic thymic carcinoid: a case report. Am Surg; 2005 Jul;71(7):578-80
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic thymic carcinoid: a case report.
  • Thymic neuroendocrine carcinomas (carcinoid) are rare tumors.
  • This report describes a patient who was diagnosed with thymic carcinoid and Cushing syndrome at age 19 that, despite complete surgical excision of his tumor, developed local recurrence with distant metastases to his brain, lungs, and bone.
  • We discuss the evolution of this patient's illness as well as the therapies used in his care.
  • Due to the nature of these tumors to recur both locally and distant, the importance of aggressive surgical management is emphasized.
  • We also discuss the role of adjuvant therapy, which in our case consisted of chemotherapy, radiotherapy, and several new therapies including an antiangiogenesis agent and a tyrosine kinase inhibitor.
  • [MeSH-major] Carcinoma, Neuroendocrine / secondary. Carcinoma, Neuroendocrine / surgery. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Palliative Care / methods. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Neoplasm Staging. Thymectomy / methods

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16089122.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Bouvier N, Zengerling V, Halley A, Le Pennec V, Le Rochais JP, Madelaine J, Galateau-Salle F, Bergot E, Zalcman G: [Primitive metastasizing bronchial carcinoid with long survival]. Rev Mal Respir; 2007 Jan;24(1):63-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive metastasizing bronchial carcinoid with long survival].
  • [Transliterated title] Carcinoïde bronchique d'emblée multimétastatique et survie prolongée. Une entité anatomo-clinique peu connue: place de l'imagerie fonctionnelle.
  • BACKGROUND: Metastatic bronchial carcinoid tumours are rare but some patients have a prolonged survival.
  • A new functional imagery now makes it possible to supplement the assessment of the extent of disease.
  • OBSERVATION: A 57 year old patient was referred for dyspnoea on exertion revealing an upper left lobar tumour, with carcinoid syndrome.
  • The assessment enabled to find out a bronchial carcinoid tumour with liver and bone metastases, highlighted by positron-emission tomography and pentetreotide SPECT.
  • A chemotherapy proved to be ineffective and upper left lobectomy was carried out because of the risk of pulmonary atelectasis.
  • The patient was alive 44 months after diagnosis (56 months after first computed tomography).
  • CONCLUSION: Metastatic bronchial carcinoid tumours are rare.
  • They keep a metastatic potential, the histological type remaining the major prognosis factor.
  • Carcinoid syndrome is suggestive.
  • The assessment of extra-thoracic disease extent benefits by contribution of new functional imagery techniques such as the pentetreotide SPECT and positron-emission tomography.
  • The management is essentially symptomatic since there is no effective chemotherapy.
  • [MeSH-major] Bone Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Survivors. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268367.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


96. Dham A, Truskinovsky AM, Dudek AZ: Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report. J Thorac Oncol; 2008 Jan;3(1):94-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.
  • Carcinoids are malignant neuroendocrine tumors consisting of a spectrum of neoplasms from low-grade typical carcinoid to high-grade small cell carcinoma.
  • We report a case of atypical thymic carcinoid that responded to neoadjuvant therapy with octreotide and sunitinib, an oral multikinase inhibitor.
  • After 3 weeks of treatment, tumor size significantly decreased to allow for a safe surgical resection with clear margins.
  • We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / drug therapy. Indoles / therapeutic use. Octreotide / therapeutic use. Pyrroles / therapeutic use. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biopsy, Needle. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Lymphatic Diseases / pathology. Male. Necrosis / pathology. Neoplasm Staging. Pneumonectomy. Positron-Emission Tomography. Proto-Oncogene Proteins c-kit / metabolism. Radiography, Thoracic. Synaptophysin / metabolism. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166847.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Indoles; 0 / Ki-67 Antigen; 0 / Pyrroles; 0 / Synaptophysin; 0 / sunitinib; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; RWM8CCW8GP / Octreotide
  •  go-up   go-down


97. Rohaizak M, Farndon JR: Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours. ANZ J Surg; 2002 Sep;72(9):635-8
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.
  • BACKGROUND: Carcinoid tumours are rare neoplasms that secrete hormones and biogenic amines, most commonly serotonin.
  • Octreotide and long acting lanreotide are found to be useful in the management of carcinoid syndrome by its interaction with somatostatin receptor, found on the carcinoid tumour.
  • The aim of this study is to look at the efficacy of octreotide and long acting lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.
  • METHOD: The effects of octreotide and long-acting lanreotide were studied in 10 patients with symptomatic non-resectable carcinoid tumours.
  • Three patients responded only to octreotide, three patients responded to both octreotide and long-acting lanreotide and three patients only responded to long-acting lanreotide.
  • Slight reductions in 24-h urine 5-hydroxyindoleacetic acid levels occurred in three of six patients but no patients were found to have objective tumour regression on computed tomography scan.
  • CONCLUSIONS: Octreotide and long-acting lanreotide are useful palliative treatments for the control of symptoms in patients with non-resectable carcinoid tumours but there is no evidence of tumour stasis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoid Tumor / drug therapy. Octreotide / therapeutic use. Peptides, Cyclic / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12269913.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 54-16-0 / Hydroxyindoleacetic Acid; RWM8CCW8GP / Octreotide
  •  go-up   go-down


98. Kinova S, Duris I, Kratochvilova E, Ondrejka P, Payer J: Carcinoid tumors--somatostatine in the diagnosis and therapy. Bratisl Lek Listy; 2002;103(3):108-12
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid tumors--somatostatine in the diagnosis and therapy.
  • BACKGROUND: Carcinoid tumors have a neuroendocrine origin and endocrine activity is typical for them.
  • OBJECTIVES: The main objective of the present study was to determine differences in the levels of an endogenous somatostatin, a neuron specific enolase in serum and excretion of 5-HIAA in the urine in patients with carcinoid tumors and also to determine the changes of these parameters during the treatment with long acting somatostatin analogue--lanreotide.
  • SUBJECTS AND METHODS: 30 pts with carcinoid tumors (20 pts with metastatic disease, 10 pts after resection of the primary tumor without known metastases at the time of the investigation) and 12 healthy probands were included in the study.
  • Levels of neuron specific enolase in the serum and the excretion of 5-HIAA in the urine in pts with carcinoid tumors were done.
  • The estimation of these parameters were repeated in the group of pts with advanced metastatic disease during the treatment with the lanreotide.
  • The chronogram of pts with metastatic carcinoid disease shows a statistically significant differences in comparison with healthy volunteers--higher mesor and later acrophase of 24-hour rhythm (p < 0.05).
  • During the therapy with lanreotide lower mesor was observed (p < 0.05).
  • The amount of the 5-hydroxyindolacetate acid in urine in pts with metastatic carcinoid was statistically significant higher than in the pts without metastases (p < 0.001).
  • During therapy with the lanreotide the decrease in the 5-HIAA in the urine (p < 0.05) was observed.
  • Neuron specific enolase in the serum was higher in group with the metastatic disease (p < 0.001).
  • CONCLUSION: Abnormalities in the somatostatin secretion and the concentration of the neuron specific enolase in serum are useful markers for the differential diagnosis and might distinguish the carcinoid patients with and without metastases.
  • Urine excretion of 5-HIAA is a good marker of endocrine activity of the carcinoid tumor. (Fig. 4, Tab. 3, Ref. 22.)
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoid Tumor / diagnosis. Carcinoid Tumor / drug therapy. Peptides, Cyclic / therapeutic use. Somatostatin / analysis. Somatostatin / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12190042.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 54-16-0 / Hydroxyindoleacetic Acid; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


99. Kałuzny M, Bolanowski M, Sukiennik-Kujawa M, Ponikowski P, Handkiewicz-Junak D, Jarzab B, Jawiarczyk A, Syrycka J: Long-term survival and nearly asymptomatic course of carcinoid tumour with multiple metastases (treated by surgery, chemotherapy, (90)Y-DOTATATE, and LAR octreotide analogue): a case report. Endokrynol Pol; 2009 Sep-Oct;60(5):401-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival and nearly asymptomatic course of carcinoid tumour with multiple metastases (treated by surgery, chemotherapy, (90)Y-DOTATATE, and LAR octreotide analogue): a case report.
  • Carcinoids are the most common neuroendocrine tumours.
  • They are usually slowly growing, located in the small intestine, secrete serotonin, and are characterized by long survival of patients, so prognosis is generally good.
  • The most frequently encountered clinical presentations of carcinoids are intermittent abdominal pain and carcinoid syndrome (diarrhoea and flushing).
  • We report a case of carcinoid tumour with primary focus in the ileum, with an appendix infiltration, in a thirty-two-year-old woman with acute appendicitis symptoms only.
  • Carcinoid was diagnosed postoperatively by histopathological examination.
  • Partial metastases resection was performed, followed by chemotherapy, (90)Y-DOTATATE and then long-acting release octreotide analogue therapy.
  • In the meantime, severe chronic heart failure (NYHA IV) due to tricuspid combined valvular heart disease and pulmonary hypertension was diagnosed.
  • Combined therapy, typical for chronic heart failure, together with long-acting octreotide analogue highly improved the patient's heart sufficiency and reduced carcinoid syndrome symptoms.
  • The only adverse events of octreotide therapy were hyperbilirubinaemia and itching.
  • Long-term survival is typical for carcinoids, but 30-years survival has not been described in the literature yet.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Ileal Neoplasms / diagnosis. Ileal Neoplasms / therapy. Survivors
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Heart Disease / diagnosis. Carcinoid Heart Disease / therapy. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Hyperbilirubinemia / chemically induced. Liver Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Octreotide / administration & dosage

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885812.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RWM8CCW8GP / Octreotide; U3P01618RT / Fluorouracil
  •  go-up   go-down


100. Auer J, Kirchgatterer A, Berent R, Allinger S, Hinterholzer G, Höbling W, Meindl S, Oppitz P, Kalchmair J, Neuwirth G, Knoflach P: [Gastrointestinal hemorrhage needing blood transfusion as the first manifestation of small bowel carcinoid tumor]. Z Gastroenterol; 2000 Aug;38(8):631-6
Hazardous Substances Data Bank. ACENOCOUMAROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal hemorrhage needing blood transfusion as the first manifestation of small bowel carcinoid tumor].
  • Carcinoid tumors arise from enterochromaffin or enterochromaffin-like cells that are present in the gastrointestinal tract, ovaries, and lungs.
  • Over 90% of carcinoids originate in the gastrointestinal tract with the most common sites in order of frequency being the appendix, terminal ileum, rectum, and the remainder of the colon.
  • Gastroduodenal and pancreatic carcinoids are infrequent.
  • Carcinoid syndrome is associated with small intestine carcinoids in about 40%.
  • Upper gastrointestinal bleeding with melaena or hematochezia is a relatively rare early symptom of patients with small intestine carcinoid tumors.
  • Laparotomy revealed bleeding from a small submucosal malignant carcinoid tumor in small intestine and multiple large metastases within mesenteric tissue.
  • Cytotoxic chemotherapy in this adjuvant setting has not been recommended.
  • Small intestinal carcinoid tumor has to be considered as a rare cause of gastrointestinal bleeding with melaena or hematochezia.
  • Nevertheless, bleeding is a relatively rare early symptom of patients with small intestine carcinoid tumor.
  • [MeSH-major] Blood Transfusion. Carcinoid Tumor / diagnosis. Gastrointestinal Hemorrhage / etiology. Intestinal Neoplasms / diagnosis. Intestine, Small
  • [MeSH-minor] Acenocoumarol / administration & dosage. Acenocoumarol / adverse effects. Aged. Diagnosis, Differential. Humans. Male. Protein S Deficiency / drug therapy. Protein S Deficiency / genetics. Recurrence






Advertisement